BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Van Cutsem E, Rivera F, Berry S, Kretzschmar A, Michael M, DiBartolomeo M, Mazier MA, Canon JL, Georgoulias V, Peeters M, Bridgewater J, Cunningham D; First BEAT investigators. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol. 2009;20:1842-1847. [PMID: 19406901 DOI: 10.1093/annonc/mdp233] [Cited by in Crossref: 371] [Cited by in F6Publishing: 341] [Article Influence: 28.5] [Reference Citation Analysis]
Number Citing Articles
1 François E, Guérin O, Follana P, Evesque L, Mari V, Aparicio T. Use of bevacizumab in elderly patients with metastatic colorectal cancer: Review. Journal of Geriatric Oncology 2011;2:64-71. [DOI: 10.1016/j.jgo.2010.09.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
2 Mariani P. The safety of perioperative bevacizumab use. J Chir (Paris). 2010;147 Suppl 1:S12-S17. [PMID: 20172200 DOI: 10.1016/s0021-7697(10)70003-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Adam R, Haller DG, Poston G, Raoul JL, Spano JP, Tabernero J, Van Cutsem E. Toward optimized front-line therapeutic strategies in patients with metastatic colorectal cancer--an expert review from the International Congress on Anti-Cancer Treatment (ICACT) 2009. Ann Oncol. 2010;21:1579-1584. [PMID: 20219759 DOI: 10.1093/annonc/mdq043] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 3.2] [Reference Citation Analysis]
4 Xu J, Qin X, Wang J, Zhang S, Zhong Y, Ren L, Wei Y, Zeng S, Wan D, Zheng S; Society of Surgery; Chinese Medical Association; Committee of Colorectal Cancer, Chinese Anti-cancer Association. Chinese guidelines for the diagnosis and comprehensive treatment of hepatic metastasis of colorectal cancer. J Cancer Res Clin Oncol. 2011;137:1379-1396. [PMID: 21796415 DOI: 10.1007/s00432-011-0999-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
5 Meadows KL, Hurwitz HI. Anti-VEGF therapies in the clinic. Cold Spring Harb Perspect Med 2012;2:a006577. [PMID: 23028128 DOI: 10.1101/cshperspect.a006577] [Cited by in Crossref: 132] [Cited by in F6Publishing: 124] [Article Influence: 13.2] [Reference Citation Analysis]
6 Gordon MS. Antiangiogenic therapies: is VEGF-A inhibition alone enough? Expert Rev Anticancer Ther 2011;11:485-96. [PMID: 21417860 DOI: 10.1586/era.11.5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
7 Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken J, Aderka D, Aranda Aguilar E, Bardelli A, Benson A, Bodoky G, Ciardiello F, D'hoore A, Diaz-rubio E, Douillard J, Ducreux M, Falcone A, Grothey A, Gruenberger T, Haustermans K, Heinemann V, Hoff P, Köhne C, Labianca R, Laurent-puig P, Ma B, Maughan T, Muro K, Normanno N, Österlund P, Oyen W, Papamichael D, Pentheroudakis G, Pfeiffer P, Price T, Punt C, Ricke J, Roth A, Salazar R, Scheithauer W, Schmoll H, Tabernero J, Taïeb J, Tejpar S, Wasan H, Yoshino T, Zaanan A, Arnold D. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Annals of Oncology 2016;27:1386-422. [DOI: 10.1093/annonc/mdw235] [Cited by in Crossref: 1387] [Cited by in F6Publishing: 1250] [Article Influence: 231.2] [Reference Citation Analysis]
8 Cohn AL, Yoshino T, Heinemann V, Obermannova R, Bodoky G, Prausová J, Garcia-Carbonero R, Ciuleanu T, Garcia-Alfonso P, Portnoy DC, Van Cutsem E, Yamazaki K, Clingan PR, Polikoff J, Lonardi S, O'Brien LM, Gao L, Yang L, Ferry D, Nasroulah F, Tabernero J. Exposure-response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial. Cancer Chemother Pharmacol 2017;80:599-608. [PMID: 28744667 DOI: 10.1007/s00280-017-3380-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
9 Gibbs P, Gebski V, Van Buskirk M, Thurston K, Cade DN, Van Hazel GA. Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: the SIRFLOX study. BMC Cancer. 2014;14:897. [PMID: 25487708 DOI: 10.1186/1471-2407-14-897] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 4.6] [Reference Citation Analysis]
10 Hurwitz HI, Tebbutt NC, Kabbinavar F, Giantonio BJ, Guan ZZ, Mitchell L, Waterkamp D, Tabernero J. Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials. Oncologist. 2013;18:1004-1012. [PMID: 23881988 DOI: 10.1634/theoncologist.2013-0107] [Cited by in Crossref: 155] [Cited by in F6Publishing: 142] [Article Influence: 17.2] [Reference Citation Analysis]
11 Ghiringhelli F, Vincent J, Beltjens F, Bengrine L, Ladoire S. Fluorouracil, leucovorin and irinotecan associated with aflibercept can induce microscopic colitis in metastatic colorectal cancer patients. Invest New Drugs. 2015;33:1263-1266. [PMID: 26490656 DOI: 10.1007/s10637-015-0295-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
12 Komatsu Y, Yuki S, Sogabe S, Fukushima H, Nakatsumi H, Kobayashi Y, Iwanaga I, Nakamura M, Hatanaka K, Miyagishima T, Kudo M, Munakata M, Meguro T, Tateyama M, Sakata Y. Phase II study of combined chemotherapy with irinotecan and S-1 (IRIS) plus bevacizumab in patients with inoperable recurrent or advanced colorectal cancer. Acta Oncol 2012;51:867-72. [PMID: 22554343 DOI: 10.3109/0284186X.2012.682629] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
13 Ozaki Y, Yoshimura A, Sawaki M, Hattori M, Gondo N, Kotani H, Adachi Y, Kataoka A, Sugino K, Horisawa N, Endo Y, Nozawa K, Sakamoto S, Iwata H. Mechanisms and anatomical risk factors of pneumothorax after Bevacizumab use: A case report. World J Clin Oncol 2020; 11(7): 504-509 [PMID: 32821655 DOI: 10.5306/wjco.v11.i7.504] [Reference Citation Analysis]
14 Chu E. An update on the current and emerging targeted agents in metastatic colorectal cancer. Clin Colorectal Cancer 2012;11:1-13. [PMID: 21752724 DOI: 10.1016/j.clcc.2011.05.005] [Cited by in Crossref: 82] [Cited by in F6Publishing: 81] [Article Influence: 7.5] [Reference Citation Analysis]
15 Sarmiento R, Longo R, Gasparini G. Antiangiogenic therapy of colorectal cancer: state of the art, challenges and new approaches. Int J Biol Markers 2012;27:e286-94. [PMID: 23280126 DOI: 10.5301/JBM.2012.10441] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
16 Zhang B, Fang C, Deng D, Xia L. Research progress on common adverse events caused by targeted therapy for colorectal cancer. Oncol Lett 2018;16:27-33. [PMID: 29928383 DOI: 10.3892/ol.2018.8651] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
17 Ruiz-Millo O, Albert-Mari A, Sendra-Garcia A, Jimenez-Torres NV. Comparative cost-effectiveness of bevacizumab-irinotecan-fluorouracil versus irinotecan-fluorouracil in first-line metastatic colorectal cancer. J Oncol Pharm Pract 2014;20:341-50. [PMID: 24177355 DOI: 10.1177/1078155213508437] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
18 Bang YH, Hong YS, Lee JS, Lee KW, Han HS, Kim SY, Kim JW, Kim HK, Kim JW, Eun CK, Kim TW, Kim JE. Effectiveness of Combining Bevacizumab With First-Line Chemotherapy Regimens for Metastatic Colorectal Cancer in Real-World Practice. Clin Colorectal Cancer 2021;20:101-112.e6. [PMID: 33223477 DOI: 10.1016/j.clcc.2020.10.001] [Reference Citation Analysis]
19 Johnsson A, Hagman H, Frödin JE, Berglund A, Keldsen N, Fernebro E, Sundberg J, De Pont Christensen R, Garm Spindler KL, Bergström D. A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial. Ann Oncol. 2013;24:2335-2341. [PMID: 23788755 DOI: 10.1093/annonc/mdt236] [Cited by in Crossref: 53] [Cited by in F6Publishing: 50] [Article Influence: 5.9] [Reference Citation Analysis]
20 Wainberg ZA, Messersmith WA, Peddi PF, Kapp AV, Ashkenazi A, Royer-Joo S, Portera CC, Kozloff MF. A phase 1B study of dulanermin in combination with modified FOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer. Clin Colorectal Cancer 2013;12:248-54. [PMID: 24075777 DOI: 10.1016/j.clcc.2013.06.002] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 4.0] [Reference Citation Analysis]
21 Căinap C, Bochiş OV, Vlad C, Popita R, Achimaş-Cadariu P, Havasi A, Vidrean A, Dranca A, Piciu A, Constantin AM, Tat T, Dana M, Crişan O, Cioban CV, Bălăcescu O, Coza O, Bălăcescu L, Marta MM, Bota M, Căinap S. Doubling the Dose of Bevacizumab Beyond Progression in Metastatic Colorectal Cancer-the Experience of a Tertiary Cancer Center. Front Pharmacol 2021;12:487316. [PMID: 33776758 DOI: 10.3389/fphar.2021.487316] [Reference Citation Analysis]
22 Hong YS, Lee J, Kim KP, Lee JL, Park YS, Park JO, Park SH, Kim SY, Baek JY, Kim JH. Multicenter phase II study of second-line bevacizumab plus doublet combination chemotherapy in patients with metastatic colorectal cancer progressed after upfront bevacizumab plus doublet combination chemotherapy. Invest New Drugs. 2013;31:183-191. [PMID: 22782485 DOI: 10.1007/s10637-012-9853-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
23 Ren T, Wang S, Shen Z, Xu C, Zhang Y, Hui F, Qi X, Zhao Q. Efficacy and Safety of Bevacizumab Plus Oxaliplatin- or Irinotecan-Based Doublet Backbone Chemotherapy as the First-Line Treatment of Metastatic Colorectal Cancer: A Systematic Review and Meta-analysis. Drug Saf 2021;44:29-40. [PMID: 33180265 DOI: 10.1007/s40264-020-00997-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Yu X, Li Z, Yu J, Chan MT, Wu WK. MicroRNAs predict and modulate responses to chemotherapy in colorectal cancer. Cell Prolif 2015;48:503-10. [PMID: 26202377 DOI: 10.1111/cpr.12202] [Cited by in Crossref: 39] [Cited by in F6Publishing: 42] [Article Influence: 5.6] [Reference Citation Analysis]
25 Eveno C, le Maignan C, Soyer P, Camus M, Barranger E, Pocard M. Late anastomotic colonic dehiscence due to antiangiogenic treatment, a specific drug-class complication requiring specific treatment: An example of pazopanib complication. Clinics and Research in Hepatology and Gastroenterology 2011;35:135-9. [DOI: 10.1016/j.clinre.2010.10.003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
26 Guan ZZ, Xu JM, Luo RC, Feng FY, Wang LW, Shen L, Yu SY, Ba Y, Liang J, Wang D, Qin SK, Wang JJ, He J, Qi C, Xu RH. Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial. Chin J Cancer 2011;30:682-9. [PMID: 21959045 DOI: 10.5732/cjc.011.10188] [Cited by in Crossref: 69] [Cited by in F6Publishing: 69] [Article Influence: 7.7] [Reference Citation Analysis]
27 Lang I, Inbar MJ, Kahán Z, Greil R, Beslija S, Stemmer SM, Kaufman B, Zvirbule Z, Steger GG, Messinger D, Brodowicz T, Zielinski C. Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer. Eur J Cancer 2012;48:3140-9. [PMID: 22640829 DOI: 10.1016/j.ejca.2012.04.022] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
28 Ngamphaiboon N, Frustino JL, Kossoff EB, Sullivan MA, O'connor TL. Osteonecrosis of The Jaw: Dental Outcomes in Metastatic Breast Cancer Patients Treated With Bisphosphonates With/Without Bevacizumab. Clinical Breast Cancer 2011;11:252-7. [DOI: 10.1016/j.clbc.2011.02.001] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
29 Yang KM, Park IJ, Lee JL, Kim CW, Yoon YS, Lim S, Yu CS, Kim JC. Benefits of repeated resections for liver and lung metastases from colorectal cancer. Asian Journal of Surgery 2020;43:102-9. [DOI: 10.1016/j.asjsur.2019.03.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
30 Connor AA, Burkes R, Gallinger S. Strategies in the Multidisciplinary Management of Synchronous Colorectal Cancer and Resectable Liver Metastases. Curr Colorectal Cancer Rep 2014;10:227-38. [DOI: 10.1007/s11888-014-0222-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
31 Suenaga M, Mizunuma N, Matsusaka S, Shinozaki E, Ueno M, Yamaguchi T. Retrospective analysis on the efficacy of bevacizumab with FOLFOX as a first-line treatment in Japanese patients with metastatic colorectal cancer. Asia Pac J Clin Oncol 2014;10:322-9. [PMID: 23915091 DOI: 10.1111/ajco.12094] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
32 Abu-Hejleh T, Mezhir JJ, Goodheart MJ, Halfdanarson TR. Incidence and management of gastrointestinal perforation from bevacizumab in advanced cancers. Curr Oncol Rep. 2012;14:277-284. [PMID: 22532266 DOI: 10.1007/s11912-012-0238-8] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
33 Simillis C, Kalakouti E, Afxentiou T, Kontovounisios C, Smith JJ, Cunningham D, Adamina M, Tekkis PP. Primary Tumor Resection in Patients with Incurable Localized or Metastatic Colorectal Cancer: A Systematic Review and Meta-analysis. World J Surg 2019;43:1829-40. [DOI: 10.1007/s00268-019-04984-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
34 Chen Z, Guo W, Cao J, Lv F, Zhang W, Qiu L, Li W, Ji D, Zhang S, Xia Z, Wang J, Li J. Endostar in combination with modified FOLFOX6 as an initial therapy in advanced colorectal cancer patients: a phase I clinical trial. Cancer Chemother Pharmacol 2015;75:547-57. [PMID: 25572362 DOI: 10.1007/s00280-014-2656-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
35 van Hellemond I, Creemers G, van Warmerdam L, de Jong F, Koornstra R. Panitumumab Monotherapy as a Second-line Treatment in Metastasised Colorectal Cancer: A Single Centre Experience. Clinical Oncology 2014;26:135-41. [DOI: 10.1016/j.clon.2013.10.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
36 Selcukbiricik F, Bilici A, Tural D, Erdamar S, Soyluk O, Buyukunal E, Demirelli F, Serdengecti S. Are high initial CEA and CA 19-9 levels associated with the presence of K-ras mutation in patients with metastatic colorectal cancer? Tumour Biol. 2013;34:2233-2239. [PMID: 23625655 DOI: 10.1007/s13277-013-0763-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
37 Borofsky SE, Levine MS, Rubesin SE, Tanyi JL, Chu CS, Lev-toaff AS. Bevacizumab-induced perforation of the gastrointestinal tract: clinical and radiographic findings in 11 patients. Abdom Imaging 2013;38:265-72. [DOI: 10.1007/s00261-012-9913-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
38 Jain VK, Hawkes EA, Cunningham D. Integration of biologic agents with cytotoxic chemotherapy in metastatic colorectal cancer. Clin Colorectal Cancer 2011;10:245-57. [PMID: 21729675 DOI: 10.1016/j.clcc.2011.04.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
39 Tuca A, Gallego R, Ghanem I, Gil-Raga M, Feliu J. Chemotherapy and Targeted Agents in the Treatment of Elderly Patients with Metastatic Colorectal Cancer. J Clin Med 2020;9:E4015. [PMID: 33322567 DOI: 10.3390/jcm9124015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Doi A, Kuboki Y, Shitara K, Fukuoka S, Bando H, Okamoto W, Kojima T, Doi T, Ohtsu A, Yoshino T. Gastrointestinal Perforation and Fistula Formation in 5 Patients With Colorectal Cancer During Treatment With Regorafenib. Clin Colorectal Cancer 2016:S1533-0028(16)30257-2. [PMID: 28089507 DOI: 10.1016/j.clcc.2016.11.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
41 Geva R, Vecchione L, Tejpar S, Piessevaux H, Van Cutsem E, Prenen H. Bevacizumab plus chemotherapy as salvage treatment in chemorefractory patients with metastatic colorectal cancer. Onco Targets Ther. 2013;6:53-58. [PMID: 23378775 DOI: 10.2147/ott.s41383] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
42 Yoshida N, Taguchi T, Nakanishi M, Inoue K, Okayama T, Ishikawa T, Otsuji E, Takayama K, Kuroboshi H, Kanazawa M, Itoh Y. Efficacy of the combination use of aprepitant and palonosetron for improving nausea in various moderately emetogenic chemotherapy regimens. BMC Pharmacol Toxicol 2019;20:6. [PMID: 30642399 DOI: 10.1186/s40360-018-0278-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
43 Parikh AA, Ni S, Koyama T, Pawlik TM, Penson D. Trends in the multimodality treatment of resectable colorectal liver metastases: an underutilized strategy. J Gastrointest Surg 2013;17:1938-46. [PMID: 24018590 DOI: 10.1007/s11605-013-2325-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
44 Fiala O, Ostasov P, Sorejs O, Liska V, Buchler T, Poprach A, Finek J. Incidental Use of Beta-Blockers Is Associated with Outcome of Metastatic Colorectal Cancer Patients Treated with Bevacizumab-Based Therapy: A Single-Institution Retrospective Analysis of 514 Patients. Cancers (Basel) 2019;11:E1856. [PMID: 31769417 DOI: 10.3390/cancers11121856] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
45 Lee SJ, Lee I, Lee J, Park C, Kang WK. Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, potentiate the anti-angiogenic effects of bevacizumab by suppressing angiopoietin2, BiP, and Hsp90α in human colorectal cancer. Br J Cancer. 2014;111:497-505. [PMID: 24945998 DOI: 10.1038/bjc.2014.283] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 3.3] [Reference Citation Analysis]
46 Zhang C, Wang J, Gu H, Zhu D, Li Y, Zhu P, Wang Y, Wang J. Capecitabine plus oxaliplatin compared with 5-fluorouracil plus oxaliplatin in metastatic colorectal cancer: Meta-analysis of randomized controlled trials. Oncol Lett. 2012;3:831-838. [PMID: 22741002 DOI: 10.3892/ol.2012.567] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.1] [Reference Citation Analysis]
47 Patel JN, Jiang C, Hertz DL, Mulkey FA, Owzar K, Halabi S, Ratain MJ, Friedman PN, Small EJ, Carducci MA, Mahoney JF, Kelley MJ, Morris MJ, Kelly WK, McLeod HL. Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance). Cancer 2015;121:1025-31. [PMID: 25417775 DOI: 10.1002/cncr.29169] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
48 Power DG, Lichtman SM. Chemotherapy for the Elderly Patient With Colorectal Cancer. The Cancer Journal 2010;16:241-52. [DOI: 10.1097/ppo.0b013e3181e07690] [Cited by in Crossref: 18] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
49 Okuno M, Hatano E, Nakamura K, Miyagawa-hayashino A, Kasai Y, Nishio T, Seo S, Taura K, Uemoto S. Regorafenib suppresses sinusoidal obstruction syndrome in rats. Journal of Surgical Research 2015;193:693-703. [DOI: 10.1016/j.jss.2014.08.052] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
50 Moscetti L, Nelli F, Fabbri MA, Sperduti I, Alesini D, Cortesi E, Gemma D, Gamucci T, Grande R, Pavese I. Maintenance single-agent bevacizumab or observation after first-line chemotherapy in patients with metastatic colorectal cancer: a multicenter retrospective study. Invest New Drugs. 2013;31:1035-1043. [PMID: 23417697 DOI: 10.1007/s10637-013-9936-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
51 Bouganim N, Mamo A, Wasserman DW, Batist G, Metrakos P, Chaudhury P, Hassanain M, Kavan P. Bevacizumab-based therapy for colorectal cancer: experience from a large Canadian cohort at the Jewish General Hospital between 2004 and 2009. Curr Oncol 2013;20:247-51. [PMID: 24155628 DOI: 10.3747/co.20.1370] [Reference Citation Analysis]
52 Li CC, Tsai HL, Huang CW, Yeh YS, Tsai TH, Wang JY. Iatrogenic pseudoaneurysm after bevacizumab therapy in patients with metastatic colorectal cancer: Two case reports. Mol Clin Oncol 2018;9:499-503. [PMID: 30345042 DOI: 10.3892/mco.2018.1712] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
53 Power DG, Lichtman SM. Resection of colorectal liver metastases: only for younger patients? Lancet Oncol 2010;11:116. [PMID: 20152768 DOI: 10.1016/S1470-2045(09)70403-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
54 Sogabe S, Komatsu Y, Yuki S, Kusumi T, Hatanaka K, Nakamura M, Kato T, Miyagishima T, Hosokawa A, Iwanaga I, Sakata Y, Asaka M. Retrospective cohort study on the safety and efficacy of bevacizumab with chemotherapy for metastatic colorectal cancer patients: the HGCSG0801 study. Jpn J Clin Oncol 2011;41:490-7. [PMID: 21303790 DOI: 10.1093/jjco/hyr008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
55 Franchi M, Barni S, Tagliabue G, Ricci P, Mazzucco W, Tumino R, Caputo A, Corrao G; GRETA working group. Effectiveness of First-Line Bevacizumab in Metastatic Colorectal Cancer: The Observational Cohort Study GRETA. Oncologist 2019;24:358-65. [PMID: 30097524 DOI: 10.1634/theoncologist.2017-0314] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
56 Wanebo HJ, Legolvan M, Paty PB, Saha S, Zuber M, D’angelica MI, Kemeny NE. Meeting the biologic challenge of colorectal metastases. Clin Exp Metastasis 2012;29:821-39. [DOI: 10.1007/s10585-012-9517-x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 3.3] [Reference Citation Analysis]
57 Petrelli F, Coinu A, Ghilardi M, Cabiddu M, Zaniboni A, Barni S. Efficacy of oxaliplatin-based chemotherapy + bevacizumab as first-line treatment for advanced colorectal cancer: a systematic review and pooled analysis of published trials. Am J Clin Oncol 2015;38:227-33. [PMID: 25806713 DOI: 10.1097/COC.0b013e3182a2d7b8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
58 Leite D, Kater FR. Conversion treatment of hepatic metastases of colon adenocarcinoma by bevacizumab and FOLFOX. Anticancer Drugs 2011;22 Suppl 2:S1-7. [PMID: 21768791 DOI: 10.1097/01.cad.0000398726.60837.27] [Reference Citation Analysis]
59 Bruera G, Cannita K, Giordano AV, Vicentini R, Ficorella C, Ricevuto E. Effectiveness and safety of intensive triplet chemotherapy plus bevacizumab, FIr-B/FOx, in young-elderly metastatic colorectal cancer patients. Biomed Res Int 2013;2013:143273. [PMID: 24307987 DOI: 10.1155/2013/143273] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
60 Maurea N, Spallarossa P, Cadeddu C, Madonna R, Mele D, Monte I, Novo G, Pagliaro P, Pepe A, Tocchetti CG, Zito C, Mercuro G. A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology. J Cardiovasc Med (Hagerstown) 2016;17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection:e93-e104. [PMID: 27755247 DOI: 10.2459/JCM.0000000000000383] [Cited by in Crossref: 28] [Cited by in F6Publishing: 8] [Article Influence: 5.6] [Reference Citation Analysis]
61 Keikes L, Koopman M, Stuiver MM, Lemmens VEPP, van Oijen MGH, Punt CJA. Practice variation on hospital level in the systemic treatment of metastatic colorectal cancer in The Netherlands: a population-based study. Acta Oncol 2020;59:395-403. [PMID: 32048563 DOI: 10.1080/0284186X.2020.1722320] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
62 Fiala O, Buchler T, Mohelnikova-Duchonova B, Melichar B, Matejka VM, Holubec L, Kulhankova J, Bortlicek Z, Bartouskova M, Liska V, Topolcan O, Sedivcova M, Finek J. G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab. Tumour Biol 2016;37:6823-30. [PMID: 26662311 DOI: 10.1007/s13277-015-4523-7] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
63 Ismaili N. Treatment of colorectal liver metastases. World J Surg Oncol. 2011;9:154. [PMID: 22115124 DOI: 10.1186/1477-7819-9-154] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 4.0] [Reference Citation Analysis]
64 Neuzillet C, Rousseau B, Kocher H, Bourget P, Tournigand C. Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers Part 1: GI carcinomas. Pharmacol Ther. 2017;174:145-172. [PMID: 28223233 DOI: 10.1016/j.pharmthera.2017.02.028] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
65 Uguen T, Leconte B, Desgrippes R, Tchoundeu B, Bretagne JF, Manfredi S. First description of an uterine perforation potentially imputable to treatment with bevacizumab. Acta Oncol 2012;51:1102-4. [PMID: 23020310 DOI: 10.3109/0284186X.2012.689855] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
66 Cersosimo RJ. Management of advanced colorectal cancer, Part 2. Am J Health Syst Pharm. 2013;70:491-506. [PMID: 23456402 DOI: 10.2146/ajhp110532b] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
67 Rossi L, Zullo A, Zoratto F, Papa A, Strudel M, Colonna M, Tomao S. Chemotherapy and target therapy as neo-adjuvant approach for initially unresectable colorectal liver metastases. Oncol Rev 2012;6:e6. [PMID: 25992208 DOI: 10.4081/oncol.2012.e6] [Reference Citation Analysis]
68 Verhoef C, de Wilt JH, Burger JW, Verheul HM, Koopman M. Surgery of the primary in stage IV colorectal cancer with unresectable metastases. Eur J Cancer. 2011;47 Suppl 3:S61-S66. [PMID: 21944031 DOI: 10.1016/s0959-8049(11)70148-4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
69 Renz P, Wegner RE, Hasan S, Brookover R, Finley G, Monga D, Raj M, McCormick J, Kirichenko A. Survival Outcomes After Surgical Management of the Primary Tumor With and Without Radiotherapy for Metastatic Rectal Adenocarcinoma: A National Cancer Database (NCDB) Analysis. Clin Colorectal Cancer 2019;18:e237-43. [PMID: 30905549 DOI: 10.1016/j.clcc.2018.12.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
70 Rosati G, Cordio S, Aprile G, Butera A, Avallone A, Di Lucca G, De Pauli F, Parra HS, Reggiardo G, Bordonaro R. Discontinuation of bevacizumab and FOLFIRI administered up to a maximum of 12 cycles as first-line therapy for metastatic colorectal cancer: a retrospective Italian study. Invest New Drugs. 2012;30:1978-1983. [PMID: 21769636 DOI: 10.1007/s10637-011-9721-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
71 Lam VW, Laurence JM, Johnston E, Hollands MJ, Pleass HC, Richardson AJ. A systematic review of two-stage hepatectomy in patients with initially unresectable colorectal liver metastases. HPB (Oxford) 2013;15:483-91. [PMID: 23750490 DOI: 10.1111/j.1477-2574.2012.00607.x] [Cited by in Crossref: 119] [Cited by in F6Publishing: 102] [Article Influence: 11.9] [Reference Citation Analysis]
72 Hofheinz R, Petersen V, Kindler M, Schulze M, Seraphin J, Hoeffkes HG, Valdix AR, Schroeder J, Herrenberger J, Stein A. Bevacizumab in first-line treatment of elderly patients with metastatic colorectal cancer: German community-based observational cohort study results. BMC Cancer. 2014;14:761. [PMID: 25311943 DOI: 10.1186/1471-2407-14-761] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
73 Grapsa D, Syrigos K, Saif MW. Bevacizumab in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for first-line and maintenance treatment of metastatic colorectal cancer. Expert Rev Anticancer Ther 2015;15:1267-81. [PMID: 26506906 DOI: 10.1586/14737140.2015.1102063] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
74 Kato S, Andoh H, Gamoh M, Yamaguchi T, Murakawa Y, Shimodaira H, Takahashi S, Mori T, Ohori H, Maeda S, Suzuki T, Kato S, Akiyama S, Sasaki Y, Yoshioka T, Ishioka C. Safety Verification Trials of mFOLFIRI and Sequential Irinotecan + Bevacizumab as First- or Second-Line Therapies for Metastatic Colorectal Cancer in Japanese Patients. Oncology 2012;83:101-7. [DOI: 10.1159/000339541] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
75 Palmela C, Gouveia C, Fidalgo C, Ferreira AO. Rare case of a giant duodenal ulcer penetrating the pancreas during antiangiogenic treatment. BMJ Case Rep 2019;12:e228612. [PMID: 31061194 DOI: 10.1136/bcr-2018-228612] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
76 Decoster L, Kenis C, Naessens B, Houbier G, De Man M, Lambrecht G, Monsaert E, Moons V, Vergauwe P, Prenen H, Van Cutsem E, Wildiers H. Integrating geriatric assessment in the first line chemotherapy treatment in older patients with metastatic colorectal cancer: Results of a prospective observational cohort study (AVAPLUS). Journal of Geriatric Oncology 2018;9:93-101. [DOI: 10.1016/j.jgo.2017.10.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
77 Yamakawa M, Doh SJ, Santosa SM, Montana M, Qin EC, Kong H, Han KY, Yu C, Rosenblatt MI, Kazlauskas A, Chang JH, Azar DT. Potential lymphangiogenesis therapies: Learning from current antiangiogenesis therapies-A review. Med Res Rev 2018;38:1769-98. [PMID: 29528507 DOI: 10.1002/med.21496] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
78 Choueiri TK, Schutz FA, Je Y, Rosenberg JE, Bellmunt J. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol 2010;28:2280-5. [PMID: 20351323 DOI: 10.1200/JCO.2009.27.2757] [Cited by in Crossref: 302] [Cited by in F6Publishing: 109] [Article Influence: 25.2] [Reference Citation Analysis]
79 Fakih M. The evolving role of VEGF-targeted therapies in the treatment of metastatic colorectal cancer. Expert Rev Anticancer Ther. 2013;13:427-438. [PMID: 23432698 DOI: 10.1586/era.13.20] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
80 Miles D, Bridgewater J, Ellis P, Harrison M, Nathan P, Nicolson M, Raouf S, Wheatley D, Plummer C. Using bevacizumab to treat metastatic cancer: UK consensus guidelines. Br J Hosp Med (Lond) 2010;71:670-7. [PMID: 21135762 DOI: 10.12968/hmed.2010.71.12.670] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
81 Zhang Y, Yang H, Zhao M, He J. Bilateral pneumothorax after bevacizumab-containing chemotherapy in fibrosarcoma. J Thorac Dis 2012;4:229-31. [PMID: 22833836 DOI: 10.3978/j.issn.2072-1439.2012.01.03] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
82 Alam W, Bouferraa Y, Haibe Y, Mukherji D, Shamseddine A. Management of colorectal cancer in the era of COVID-19: Challenges and suggestions. Sci Prog 2021;104:368504211010626. [PMID: 33878982 DOI: 10.1177/00368504211010626] [Reference Citation Analysis]
83 Razenberg LG, van Gestel YR, de Hingh IH, Loosveld OJ, Vreugdenhil G, Beerepoot LV, Creemers GJ, Lemmens VE. Bevacizumab for metachronous metastatic colorectal cancer: a reflection of community based practice. BMC Cancer 2016;16:110. [PMID: 26882902 DOI: 10.1186/s12885-016-2158-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
84 Cartwright TH. Adverse events associated with antiangiogenic agents in combination with cytotoxic chemotherapy in metastatic colorectal cancer and their management. Clin Colorectal Cancer. 2013;12:86-94. [PMID: 23562587 DOI: 10.1016/j.clcc.2012.12.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
85 Bai L, Zhang DS, Wu WJ, Ren C, Wang DS, Wang F, Qiu MZ, Xu RH. Clinical outcomes of Chinese patients with metastatic colorectal cancer receiving first-line bevacizumab-containing treatment. Med Oncol. 2015;32:469. [PMID: 25582893 DOI: 10.1007/s12032-014-0469-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
86 Cremolini C, Schirripa M, Antoniotti C, Moretto R, Salvatore L, Masi G, Falcone A, Loupakis F. First-line chemotherapy for mCRC—a review and evidence-based algorithm. Nat Rev Clin Oncol 2015;12:607-19. [PMID: 26215044 DOI: 10.1038/nrclinonc.2015.129] [Cited by in Crossref: 91] [Cited by in F6Publishing: 86] [Article Influence: 13.0] [Reference Citation Analysis]
87 Bertaut A, Touchefeu Y, Blanc J, Bouché O, François E, Conroy T, Artru P, Adenis A, Gobbo J, Borg C, Ghiringhelli F, Bennouna J. Health-Related Quality of Life Analysis in Metastatic Colorectal Cancer Patients Treated by Second-Line Chemotherapy, Associated With Either Cetuximab or Bevacizumab: The PRODIGE 18 Randomized Phase II Study. Clin Colorectal Cancer 2021:S1533-0028(21)00087-6. [PMID: 34838460 DOI: 10.1016/j.clcc.2021.09.001] [Reference Citation Analysis]
88 Raghav KPS, Eng C. Role of the MET–HGF axis in colorectal cancer: precepts and prospects. Colorectal Cancer 2012;1:329-41. [DOI: 10.2217/crc.12.40] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
89 Baxter NN, Sutradhar R, Dossa F, Fu L, Rochon P, Wei AC, Kennedy ED, Earle CC. Does the presence of an intact primary increase the risk of nonelective colorectal surgery in patients treated with bevacizumab? Colorectal Dis 2020;22:1974-83. [PMID: 32767608 DOI: 10.1111/codi.15294] [Reference Citation Analysis]
90 Castel M, Despas F, Modesto A, Gales C, Honton B, Galinier M, Senard JM, Pathak A. [Cardiotoxicity of chemotherapies]. Presse Med. 2013;42:26-39. [PMID: 22727981 DOI: 10.1016/j.lpm.2012.04.014] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
91 Okines A, Cunningham D. Current perspective: Bevacizumab in colorectal cancer – A time for reappraisal? European Journal of Cancer 2009;45:2452-61. [DOI: 10.1016/j.ejca.2009.06.028] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
92 Bruera G, Santomaggio A, Cannita K, Baldi PL, Tudini M, De Galitiis F, Mancini M, Marchetti P, Antonucci A, Ficorella C, Ricevuto E. "Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study. BMC Cancer 2010;10:567. [PMID: 20958992 DOI: 10.1186/1471-2407-10-567] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 2.8] [Reference Citation Analysis]
93 Mellor JD, Cassumbhoy M, Jefford M. Clinical guidance on the perioperative use of targeted agents in solid tumor oncology. Asia Pac J Clin Oncol 2011;7:106-13. [PMID: 21585689 DOI: 10.1111/j.1743-7563.2011.01394.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
94 Chan A, Verma S, Loibl S, Crawford J, Choi MR, Dreiling L, Vandenberg T. Reporting of myelotoxicity associated with emerging regimens for the treatment of selected solid tumors. Crit Rev Oncol Hematol 2012;81:136-50. [PMID: 21507676 DOI: 10.1016/j.critrevonc.2011.03.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
95 Kuo YH, Lin CH, Shau WY, Chen TJ, Yang SH, Huang SM, Hsu C, Lu YS, Cheng AL. Dynamics of circulating endothelial cells and endothelial progenitor cells in breast cancer patients receiving cytotoxic chemotherapy. BMC Cancer 2012;12:620. [PMID: 23268621 DOI: 10.1186/1471-2407-12-620] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
96 Chong G, Tebbutt NC. Using bevacizumab with different chemotherapeutic regimens in metastatic colorectal cancer: balancing utility with low toxicity. Ther Adv Med Oncol 2010;2:309-17. [PMID: 21789143 DOI: 10.1177/1758834010375096] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
97 Katayose Y, Unno M. Management of liver metastases from colorectal cancer. Clin J Gastroenterol 2010;3:128-35. [PMID: 26190118 DOI: 10.1007/s12328-010-0155-z] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
98 Renouf DJ, Welch S, Moore MJ, Krzyzanowska MK, Knox J, Feld R, Liu G, MacKay H, Petronis J, Wang L. A phase II study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer. Cancer Chemother Pharmacol. 2012;69:1339-1344. [PMID: 22349811 DOI: 10.1007/s00280-012-1843-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
99 Chapman SJ, McKavanagh D, Burge ME, McPherson I, Walpole E, Hollingworth SA. Effectiveness of bevacizumab and cetuximab in metastatic colorectal cancer across selected public hospitals in Queensland. Asia Pac J Clin Oncol 2017;13:e253-61. [PMID: 27435535 DOI: 10.1111/ajco.12518] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
100 François E, Mineur L, Deplanque G, Laplaige P, Smith D, Gourgou S, Tanang A, Ionescu-Goga M, Veerabudun K, Lelarge Y, Kim S, Rollot F. Efficacy and Safety of Bevacizumab Combined With First-Line Chemotherapy in Elderly (≥75 Years) Patients With Metastatic Colorectal Cancer: A Real-World Study. Clin Colorectal Cancer 2020;19:e100-9. [PMID: 32299778 DOI: 10.1016/j.clcc.2020.02.009] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
101 Siegelmann-Danieli N, Farkash A, Katzir I, Vesterman Landes J, Rotem Rabinovich H, Lomnicky Y, Carmeli B, Parush-Shear-Yashuv N. A Novel Computational Tool for Mining Real-Life Data: Application in the Metastatic Colorectal Cancer Care Setting. PLoS One 2016;11:e0154689. [PMID: 27144545 DOI: 10.1371/journal.pone.0154689] [Reference Citation Analysis]
102 Ghiringhelli F, Bichard D, Limat S, Lorgis V, Vincent J, Borg C, Berthou J, Orry D, Ortega-Deballon P, Lakkis Z, Facy O, Heyd B, Rat P, Nerich V, Ladoire S. Bevacizumab efficacy in metastatic colorectal cancer is dependent on primary tumor resection. Ann Surg Oncol 2014;21:1632-40. [PMID: 24419756 DOI: 10.1245/s10434-013-3463-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
103 Bencsikova B, Bortlicek Z, Halamkova J, Ostrizkova L, Kiss I, Melichar B, Pavlik T, Dusek L, Valik D, Vyzula R. Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view. BMC Gastroenterol. 2015;15:37. [PMID: 25888291 DOI: 10.1186/s12876-015-0266-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
104 Ascierto ML, Melero I, Ascierto PA. Melanoma: From Incurable Beast to a Curable Bet. The Success of Immunotherapy. Front Oncol 2015;5:152. [PMID: 26217587 DOI: 10.3389/fonc.2015.00152] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
105 Clarke SJ, Karapetis CS, Gibbs P, Pavlakis N, Desai J, Michael M, Tebbutt NC, Price TJ, Tabernero J. Overview of biomarkers in metastatic colorectal cancer: tumour, blood and patient-related factors. Crit Rev Oncol Hematol 2013;85:121-35. [PMID: 22762963 DOI: 10.1016/j.critrevonc.2012.06.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
106 Suo Y, Wu F, Xu P, Shi H, Wang T, Liu H, Cheng Z. NIR‐II Fluorescence Endoscopy for Targeted Imaging of Colorectal Cancer. Adv Healthcare Mater 2019;8:1900974. [DOI: 10.1002/adhm.201900974] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
107 Barugel ME, Vargas C, Krygier Waltier G. Metastatic colorectal cancer: recent advances in its clinical management. Expert Review of Anticancer Therapy 2014;9:1829-47. [DOI: 10.1586/era.09.143] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
108 Giopanou I, Pintzas A. RAS and BRAF in the foreground for non-small cell lung cancer and colorectal cancer: Similarities and main differences for prognosis and therapies. Crit Rev Oncol Hematol 2020;146:102859. [PMID: 31927392 DOI: 10.1016/j.critrevonc.2019.102859] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
109 Qu YL, Saifuding•Keyoumu, Tang Y. Efficacy and safety of bevacizumab combined with chemotherapy in treatment of metastatic colorectal cancer. Shijie Huaren Xiaohua Zazhi 2016; 24(17): 2748-2754 [DOI: 10.11569/wcjd.v24.i17.2748] [Reference Citation Analysis]
110 Buiting HM, Terpstra W, Dalhuisen F, Gunnink-Boonstra N, Sonke GS, den Hartogh G. The facilitating role of chemotherapy in the palliative phase of cancer: qualitative interviews with advanced cancer patients. PLoS One 2013;8:e77959. [PMID: 24223130 DOI: 10.1371/journal.pone.0077959] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.7] [Reference Citation Analysis]
111 Miarka L, Hauser C, Helm O, Holdhof D, Beckinger S, Egberts JH, Gundlach JP, Lenk L, Rahn S, Mikulits W, Trauzold A, Sebens S. The Hepatic Microenvironment and TRAIL-R2 Impact Outgrowth of Liver Metastases in Pancreatic Cancer after Surgical Resection. Cancers (Basel) 2019;11:E745. [PMID: 31146405 DOI: 10.3390/cancers11060745] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
112 Toumazis I, Kurt M, Toumazi A, Karacosta LG, Kwon C. Comparative Effectiveness of Up To Three Lines of Chemotherapy Treatment Plans for Metastatic Colorectal Cancer. MDM Policy Pract 2017;2:2381468317729650. [PMID: 30288431 DOI: 10.1177/2381468317729650] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
113 Shankaran V, Mummy D, Koepl L, Bansal A, Mirick DK, Yu E, Morlock R, Ogale S, Ramsey SD. Survival and lifetime costs associated with first-line bevacizumab use in older patients with metastatic colorectal cancer. Oncologist 2014;19:892-9. [PMID: 25085899 DOI: 10.1634/theoncologist.2013-0209] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
114 Kennedy AS, Ball DS, Cohen SJ, Cohn M, Coldwell DM, Drooz A, Ehrenwald E, Kanani S, Nutting CW, Moeslein FM, Putnam SG 3rd, Rose SC, Savin MA, Schirm S, Sharma NK, Wang EA. Hepatic imaging response to radioembolization with yttrium-90-labeled resin microspheres for tumor progression during systemic chemotherapy in patients with colorectal liver metastases. J Gastrointest Oncol 2015;6:594-604. [PMID: 26697190 DOI: 10.3978/j.issn.2078-6891.2015.082] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
115 Yang SH, Lin JK, Chen WS, Lin TC, Yang SH, Jiang JK, Chang SC, Lan YT, Chao TC, Yen CC, Tzeng CH, Teng HW. Pneumothorax after bevacizumab-containing chemotherapy: a case report. Jpn J Clin Oncol. 2011;41:269-271. [PMID: 21030401 DOI: 10.1093/jjco/hyq195] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
116 Raouf S, Bertelli G, Ograbek A, Field P, Tran I. Real-world use of bevacizumab in metastatic colorectal, metastatic breast, advanced ovarian and cervical cancer: a systematic literature review. Future Oncol 2019;15:543-61. [PMID: 30379088 DOI: 10.2217/fon-2018-0480] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
117 Yalcin S, Trad D, Kader YA, Halawani H, Demir OG, Mall R, Meshcheryakov A, Nasr F, Nosworthy A, Osinsky D. Personalized treatment is better than one treatment fits all in the management of patients with mCRC: a consensus statement. Future Oncol. 2014;10:2643-2657. [PMID: 25531050 DOI: 10.2217/fon.14.203] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
118 Dunn C, Hong W, Gibbs P, Ackland S, Sjoquist K, Tebbutt NC, Price T, Burge M. Personalizing First-Line Systemic Therapy in Metastatic Colorectal Cancer: Is There a Role for Initial Low-Intensity Therapy in 2021 and Beyond? A Perspective From Members of the Australasian Gastrointestinal Trials Group. Clin Colorectal Cancer 2021;20:245-55. [PMID: 34103264 DOI: 10.1016/j.clcc.2021.05.001] [Reference Citation Analysis]
119 Aguado C, García-Paredes B, Sotelo MJ, Sastre J, Díaz-Rubio E. Should capecitabine replace 5-fluorouracil in the first-line treatment of metastatic colorectal cancer? World J Gastroenterol 2014; 20(20): 6092-6101 [PMID: 24876731 DOI: 10.3748/wjg.v20.i20.6092] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
120 Glimelius B, Cavalli-Björkman N. Metastatic colorectal cancer: current treatment and future options for improved survival. Medical approach--present status. Scand J Gastroenterol 2012;47:296-314. [PMID: 22242568 DOI: 10.3109/00365521.2012.640828] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 4.1] [Reference Citation Analysis]
121 Correa E, Lindsay T, Dotan E. Management of Metastatic Colorectal Carcinoma in Older Adults: Balancing Risks and Benefits of Novel Therapies. Drugs Aging 2021;38:639-54. [PMID: 34143421 DOI: 10.1007/s40266-021-00869-z] [Reference Citation Analysis]
122 Temraz S, Mukherji D, Shamseddine A. Sequencing of treatment in metastatic colorectal cancer: Where to fit the target? World J Gastroenterol 2014; 20(8): 1993-2004 [PMID: 24616571 DOI: 10.3748/wjg.v20.i8.1993] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
123 Loupakis F, Ruzzo A, Salvatore L, Cremolini C, Masi G, Frumento P, Schirripa M, Catalano V, Galluccio N, Canestrari E. Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer. BMC Cancer. 2011;11:247. [PMID: 21669012 DOI: 10.1186/1471-2407-11-247] [Cited by in Crossref: 56] [Cited by in F6Publishing: 49] [Article Influence: 5.1] [Reference Citation Analysis]
124 Hurwitz HI, Lyman GH. Registries and Randomized Trials in Assessing the Effects of Bevacizumab in Colorectal Cancer: Is There a Common Theme? JCO 2012;30:580-1. [DOI: 10.1200/jco.2011.40.7031] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
125 Bayoglu İV, Yildiz I, Varol U, Cokmert S, Alacacıoğlu A, Kucukzeybek Y, Akyol M, Demir L, Dirican A, Tarhan O. Uracil/tegafur as a possible salvage therapy in chemo-refractory colorectal cancer patients: a single institutional retrospective study. Contemp Oncol (Pozn) 2015;19:385-90. [PMID: 26793023 DOI: 10.5114/wo.2015.53374] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
126 Hammerman A, Greenberg-dotan S, Battat E, Feldhamer I, Bitterman H, Brenner B. The ‘real-life’ impact of adding bevacizumab to first-line therapy in metastatic colorectal cancer patients: A large Israeli retrospective cohort study. Acta Oncologica 2015;54:164-70. [DOI: 10.3109/0284186x.2014.958532] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
127 Lawler M, Johnston B, Van Schaeybroeck S, Salto-tellez M, Wilson R, Dunlop M, Johnston PG. Colorectal Cancer. Abeloff's Clinical Oncology. Elsevier; 2020. pp. 1219-1280.e15. [DOI: 10.1016/b978-0-323-47674-4.00074-8] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
128 Uetake H, Tanaka S, Ishikawa T, Sugihara K, Arii S. Fate of metastatic foci after chemotherapy and usefulness of contrast-enhanced intraoperative ultrasonography to detect minute hepatic lesions. J Hepatobiliary Pancreat Sci 2012;19:509-14. [PMID: 22539087 DOI: 10.1007/s00534-012-0510-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
129 Girardi F, Franceschi E, Brandes AA. Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies. Oncologist 2010;15:683-94. [PMID: 20547589 DOI: 10.1634/theoncologist.2009-0235] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
130 Lacaze L, Scotté M. Diaphragmatic rupture, a new complication of Bevacizumab. Eur J Surg Oncol 2012;38:1079-81. [PMID: 22818843 DOI: 10.1016/j.ejso.2012.06.550] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
131 Temraz S, Mukherji D, Alameddine R, Shamseddine A. Methods of overcoming treatment resistance in colorectal cancer. Crit Rev Oncol Hematol 2014;89:217-30. [PMID: 24075059 DOI: 10.1016/j.critrevonc.2013.08.015] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 4.4] [Reference Citation Analysis]
132 Lee JJ, Chu E. Sequencing of antiangiogenic agents in the treatment of metastatic colorectal cancer. Clin Colorectal Cancer. 2014;13:135-144. [PMID: 24768040 DOI: 10.1016/j.clcc.2014.02.001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
133 Hedhli N, Russell KS. Cardiotoxicity of molecularly targeted agents. Curr Cardiol Rev 2011;7:221-33. [PMID: 22758623 DOI: 10.2174/157340311799960636] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
134 Walraven M, Witteveen PO, Lolkema MP, van Hillegersberg R, Voest EE, Verheul HM. Antiangiogenic tyrosine kinase inhibition related gastrointestinal perforations: a case report and literature review. Angiogenesis 2011;14:135-41. [PMID: 21188500 DOI: 10.1007/s10456-010-9197-6] [Cited by in Crossref: 46] [Cited by in F6Publishing: 28] [Article Influence: 3.8] [Reference Citation Analysis]
135 Ogawa K, Ueno T, Kato K, Nishitani H, Akiyoshi K, Iwasa S, Nakajima TE, Hamaguchi T, Yamada Y, Hosokawa A, Sugiyama T, Shimada Y. A retrospective analysis of periodontitis during bevacizumab treatment in metastatic colorectal cancer patients. Int J Clin Oncol 2013;18:1020-4. [DOI: 10.1007/s10147-012-0478-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
136 Pachón V, Trujillo-Santos J, Domènech P, Gallardo E, Font C, González-Porras JR, Pérez-Segura P, Maestre A, Mateo J, Muñoz A, Peris ML, Lecumberri R. Cancer-Associated Thrombosis: Beyond Clinical Practice Guidelines-A Multidisciplinary (SEMI-SEOM-SETH) Expert Consensus. TH Open 2018;2:e373-86. [PMID: 31249964 DOI: 10.1055/s-0038-1675577] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
137 Jackson CG, Sharples K, Thompson PI, O'Donnell A, Robinson BA, Perez DJ, Adams J, Isaacs R, Deva S, Hinder VA, Findlay MP. Dose-intense capecitabine, oxaliplatin and bevacizumab as first line treatment for metastatic, unresectable colorectal cancer: a multi-centre phase II study. BMC Cancer 2014;14:737. [PMID: 25274181 DOI: 10.1186/1471-2407-14-737] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
138 Schmiegel W, Reinacher-Schick A, Arnold D, Kubicka S, Freier W, Dietrich G, Geißler M, Hegewisch-Becker S, Tannapfel A, Pohl M. Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group. Ann Oncol. 2013;24:1580-1587. [PMID: 23463625 DOI: 10.1093/annonc/mdt028] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 4.9] [Reference Citation Analysis]
139 Jensen SA, Sørensen JB. 5-fluorouracil-based therapy induces endovascular injury having potential significance to development of clinically overt cardiotoxicity. Cancer Chemother Pharmacol 2012;69:57-64. [PMID: 21603868 DOI: 10.1007/s00280-011-1669-x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 41] [Article Influence: 4.7] [Reference Citation Analysis]
140 Orcutt ST, Massarweh NN, Li LT, Artinyan A, Richardson PA, Albo D, Anaya DA. Patterns of Care for Colorectal Liver Metastasis Within an Integrated Health System: Secular Trends and Outcomes. Ann Surg Oncol 2017;24:23-30. [PMID: 27342829 DOI: 10.1245/s10434-016-5351-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
141 Keating GM. Bevacizumab: a review of its use in advanced cancer. Drugs 2014;74:1891-925. [PMID: 25315029 DOI: 10.1007/s40265-014-0302-9] [Cited by in Crossref: 106] [Cited by in F6Publishing: 92] [Article Influence: 15.1] [Reference Citation Analysis]
142 Burotto M, Hartley ML, Marshall JL, Pishvaian MJ. Future of targeted agents in metastatic colorectal cancer. Colorectal Cancer 2012;1. [PMID: 24273599 DOI: 10.2217/crc.12.52] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
143 Lam VWT, Pang T, Laurence JM, Johnston E, Hollands MJ, Pleass HCC, Richardson AJ. A Systematic Review of Repeat Hepatectomy for Recurrent Colorectal Liver Metastases. J Gastrointest Surg 2013;17:1312-21. [DOI: 10.1007/s11605-013-2186-5] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 3.8] [Reference Citation Analysis]
144 Ronnekleiv-Kelly SM, Burkhart RA, Pawlik TM. Molecular markers of prognosis and therapeutic targets in metastatic colorectal cancer. Surg Oncol 2016;25:190-9. [PMID: 27566022 DOI: 10.1016/j.suronc.2016.05.018] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
145 Hong YS, Kim HJ, Park SJ, Kim KP, Lee JL, Park JH, Kim JH, Lim SB, Yu CS, Kim JC, Baek JY, Kim SY, Kim TW. Second-line cetuximab/irinotecan versus oxaliplatin/fluoropyrimidines for metastatic colorectal cancer with wild-type KRAS. Cancer Sci 2013;104:473-80. [PMID: 23298313 DOI: 10.1111/cas.12098] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
146 Chau I, Cunningham D. Bevacizumab-associated gastrointestinal perforation. The Lancet Oncology 2009;10:534-6. [DOI: 10.1016/s1470-2045(09)70142-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
147 Pawlik TM, Cosgrove D. The role of peri-operative chemotherapy for resectable colorectal liver metastasis: what does the evidence support? J Gastrointest Surg. 2011;15:410-415. [PMID: 21253876 DOI: 10.1007/s11605-011-1423-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
148 Hadian Rasanani S, Eslami Moghadam M, Soleimani E, Divsalar A, Ajloo D, Tarlani A, Amiri M. Anticancer activity of new imidazole derivative of 1R,2R-diaminocyclohexane palladium and platinum complexes as DNA fluorescent probes. Journal of Biomolecular Structure and Dynamics 2018;36:3058-76. [DOI: 10.1080/07391102.2017.1385538] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 3.6] [Reference Citation Analysis]
149 Cortellini A, Cannita K, Parisi A, Lanfiuti Baldi P, Venditti O, D'Orazio C, Dal Mas A, Calvisi G, Giordano AV, Vicentini V, Vicentini R, Felicioni L, Marchetti A, Buttitta F, Russo A, Ficorella C. Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: an update from clinical practice. Onco Targets Ther 2019;12:2159-70. [PMID: 30988620 DOI: 10.2147/OTT.S194745] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
150 Dai F, Shu L, Bian Y, Wang Z, Yang Z, Chu W, Gao S. Safety of bevacizumab in treating metastatic colorectal cancer: a systematic review and meta-analysis of all randomized clinical trials. Clin Drug Investig. 2013;33:779-788. [PMID: 23979925 DOI: 10.1007/s40261-013-0125-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
151 McIntyre WF, Oqab Z, Seaborn GE, Hopman WM, Hammad N, Baranchuk A. Changes in plasma hormones and heart rate variability in patients receiving the cardiotoxic anti-cancer agent bevacizumab. Int J Cardiol 2016;219:25-6. [PMID: 27257852 DOI: 10.1016/j.ijcard.2016.05.061] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
152 Lambrechts D, Thienpont B, Thuillier V, Sagaert X, Moisse M, Peuteman G, Pericay C, Folprecht G, Zalcberg J, Zilocchi C, Margherini E, Chiron M, Van Cutsem E. Evaluation of efficacy and safety markers in a phase II study of metastatic colorectal cancer treated with aflibercept in the first-line setting. Br J Cancer 2015;113:1027-34. [PMID: 26355232 DOI: 10.1038/bjc.2015.329] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
153 Bécouarn Y, Cany L, Pulido M, Beyssac R, Texereau P, Le Morvan V, Béchade D, Brunet R, Aitouferoukh S, Lalet C, Mathoulin-Pélissier S, Fonck M, Robert J. FOLFIRI® and bevacizumab in first-line treatment for colorectal cancer patients: safety, efficacy and genetic polymorphisms. BMC Res Notes 2014;7:260. [PMID: 24758527 DOI: 10.1186/1756-0500-7-260] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
154 Sun X, Yuan W, Hao F, Zhuang W. Promoter Methylation of RASSF1A indicates Prognosis for Patients with Stage II and III Colorectal Cancer Treated with Oxaliplatin-Based Chemotherapy. Med Sci Monit. 2017;23:5389-5395. [PMID: 29128865 DOI: 10.12659/msm.903927] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
155 Lee SJ, Lee SY, Lee WS, Yoo JS, Sun JM, Lee J, Park SH, Park JO, Ahn MJ, Lim HY, Kang WK, Park YS. Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors. Invest New Drugs 2017;35:782-90. [PMID: 28391576 DOI: 10.1007/s10637-017-0463-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
156 Cai GX, Cai SJ. Multi-modality treatment of colorectal liver metastases. World J Gastroenterol 2012; 18(1): 16-24 [PMID: 22228966 DOI: 10.3748/wjg.v18.i1.16] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
157 Millet G, Truant S, Leteurtre E, Hebbar M, Zerbib P, Huet G, Boleslawski E, Pruvot FR. Volumetric analysis of remnant liver regeneration after major hepatectomy in bevacizumab-treated patients: a case-matched study in 82 patients. Ann Surg. 2012;256:755-761; discussion 761-762. [PMID: 23095619 DOI: 10.1097/sla.0b013e31827381ca] [Cited by in Crossref: 23] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
158 Stein A, Petersen V, Schulze M, Seraphin J, Hoeffkes HG, Valdix AR, Schroeder J, Herrenberger J, Boxberger F, Leutgeb B, Hinke A, Kutscheidt A, Arnold D. Bevacizumab plus chemotherapy as first-line treatment for patients with metastatic colorectal cancer: results from a large German community-based observational cohort study. Acta Oncol 2015;54:171-8. [PMID: 25307517 DOI: 10.3109/0284186X.2014.961649] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
159 Mestier L, Manceau G, Neuzillet C, Bachet JB, Spano JP, Kianmanesh R, Vaillant JC, Bouché O, Hannoun L, Karoui M. Primary tumor resection in colorectal cancer with unresectable synchronous metastases: A review. World J Gastrointest Oncol 2014; 6(6): 156-169 [PMID: 24936226 DOI: 10.4251/wjgo.v6.i6.156] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
160 García-Alfonso P, Ferrer A, Gil S, Dueñas R, Pérez MT, Molina R, Capdevila J, Safont MJ, Castañón C, Cano JM, Lara R. Neoadjuvant and conversion treatment of patients with colorectal liver metastasis: the potential role of bevacizumab and other antiangiogenic agents. Target Oncol 2015;10:453-65. [PMID: 25752908 DOI: 10.1007/s11523-015-0362-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
161 Cao D, Guo CH, Liu JW, Yang X, Li Q. Bleeding after bevacizumab treatment in patients with metastatic colorectal cancer. Tumori 2015;101:46-51. [PMID: 25702674 DOI: 10.5301/tj.5000211] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
162 Fakih M. SIR-Spheres ® radioembolization in the management of metastatic colorectal cancer: a medical oncology perspective. Colorectal Cancer 2014;3:331-43. [DOI: 10.2217/crc.14.29] [Reference Citation Analysis]
163 Angelucci A, Delle Monache S, Cortellini A, Di Padova M, Ficorella C. "Vessels in the Storm": Searching for Prognostic and Predictive Angiogenic Factors in Colorectal Cancer. Int J Mol Sci 2018;19:E299. [PMID: 29351242 DOI: 10.3390/ijms19010299] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
164 Salvatore L, Aprile G, Arnoldi E, Aschele C, Carnaghi C, Cosimelli M, Maiello E, Normanno N, Sciallero S, Valvo F, Beretta GD. Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM). ESMO Open 2017;2:e000147. [PMID: 28761730 DOI: 10.1136/esmoopen-2016-000147] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
165 Welch S, Spithoff K, Rumble RB, Maroun J. Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review. Ann Oncol. 2010;21:1152-1162. [PMID: 19942597 DOI: 10.1093/annonc/mdp533] [Cited by in Crossref: 118] [Cited by in F6Publishing: 107] [Article Influence: 9.1] [Reference Citation Analysis]
166 Morotti M, Valenzano Menada M, Venturini PL, Ferrero S. Bevacizumab in endometrial cancer treatment. Expert Opinion on Biological Therapy 2012;12:649-58. [DOI: 10.1517/14712598.2012.672558] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
167 Cen P, Liu C, Du X. Comparison of toxicity profiles of fluorouracil versus oxaliplatin regimens in a large population-based cohort of elderly patients with colorectal cancer. Annals of Oncology 2012;23:1503-11. [DOI: 10.1093/annonc/mdr449] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
168 Wasan HS, Sangro B, Kennedy AS. Patient selection criteria for selective internal radiation therapy and integration into treatment guidelines. European Journal of Cancer Supplements 2012;10:76-80. [DOI: 10.1016/s1359-6349(12)70052-6] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
169 Chew M, Teo J, Kabir T, Koh P, Eu K, Tang C. Stage IV Colorectal Cancers: An Analysis of Factors Predicting Outcome and Survival in 728 cases. J Gastrointest Surg 2012;16:603-12. [DOI: 10.1007/s11605-011-1725-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
170 Gray EJ, Darvishzadeh A, Sharma A, Ganeshan D, Faria SC, Lall C. Cancer therapy-related complications in the bowel and mesentery: an imaging perspective. Abdom Radiol (NY) 2016;41:2031-47. [PMID: 27277528 DOI: 10.1007/s00261-016-0799-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
171 Hatano E, Okuno M, Nakamura K, Ishii T, Seo S, Taura K, Yasuchika K, Yazawa T, Zaima M, Kanazawa A. Conversion to complete resection with mFOLFOX6 with bevacizumab or cetuximab based on K-ras status for unresectable colorectal liver metastasis (BECK study). J Hepatobiliary Pancreat Sci. 2015;22:634-645. [PMID: 25926024 DOI: 10.1002/jhbp.254] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
172 Yamaue H, Tsunoda T, Tani M, Miyazawa M, Yamao K, Mizuno N, Okusaka T, Ueno H, Boku N, Fukutomi A, Ishii H, Ohkawa S, Furukawa M, Maguchi H, Ikeda M, Togashi Y, Nishio K, Ohashi Y. Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study. Cancer Sci 2015;106:883-90. [PMID: 25867139 DOI: 10.1111/cas.12674] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 6.6] [Reference Citation Analysis]
173 Kashiwa M, Matsushita R. Comparative Cost-effectiveness of Aflibercept and Ramucirumab in Combination with Irinotecan and Fluorouracil-based Therapy for the Second-line Treatment of Metastatic Colorectal Cancer in Japan. Clin Ther 2020;42:1361-75. [PMID: 32616433 DOI: 10.1016/j.clinthera.2020.05.013] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
174 Rossi L, Veltri E, Zullo A, Zoratto F, Colonna M, Di Seri M, Longo F, Mottolese M, Giannarelli D, Ruco L, Romiti A, Barucca V, Adua D, Tomao S. Bevacizumab plus chemotherapy in metastatic colorectal cancer patients treated in clinical practice. Future Oncol 2012;8:1193-7. [PMID: 23030493 DOI: 10.2217/fon.12.108] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
175 Abdali A, Baci D, Damiani I, Belloni F, De Dominicis C, Gelmi ML, Corsini A, Bellosta S. In vitro angiogenesis inhibition with selective compounds targeting the key glycolytic enzyme PFKFB3. Pharmacol Res 2021;168:105592. [PMID: 33813027 DOI: 10.1016/j.phrs.2021.105592] [Reference Citation Analysis]
176 Gustavsson B. Simultaneous surgery for primary colorectal cancer and metastatic lesions? Scandinavian Journal of Gastroenterology 2011;47:269-76. [DOI: 10.3109/00365521.2012.640824] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
177 Cainap C, Ungur RA, Bochis OV, Achimas P, Vlad C, Havasi A, Vidrean A, Farcas A, Tat T, Gherman A, Piciu A, Bota M, Constantin AM, Pop LA, Maniu D, Crisan O, Cioban CV, Balacescu O, Coza O, Balacescu L, Marta MM, Dronca E, Cainap S. Partnering bevacizumab with irinotecan as first line-therapy of metastatic colorectal cancer improves progression free survival-A retrospective analysis. PLoS One 2021;16:e0248922. [PMID: 33909622 DOI: 10.1371/journal.pone.0248922] [Reference Citation Analysis]
178 Stein A, Quidde J, Schröder JK, Göhler T, Tschechne B, Valdix AR, Höffkes HG, Schirrmacher-Memmel S, Wohlfarth T, Hinke A, Engelen A, Arnold D. Capecitabine in the routine first-line treatment of elderly patients with advanced colorectal cancer--results from a non-interventional observation study. BMC Cancer 2016;16:82. [PMID: 26865161 DOI: 10.1186/s12885-016-2113-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
179 Pessaux P. [Chemotherapy's hepatotoxicity: what is the impact on surgery?]. J Chir (Paris) 2010;147 Suppl 1:S7-S11. [PMID: 20172202 DOI: 10.1016/S0021-7697(10)70002-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
180 Riechelmann R, Grothey A. Antiangiogenic therapy for refractory colorectal cancer: current options and future strategies. Ther Adv Med Oncol 2017;9:106-26. [PMID: 28203302 DOI: 10.1177/1758834016676703] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
181 Moriwaki T, Bando H, Takashima A, Yamazaki K, Esaki T, Yamashita K, Fukunaga M, Miyake Y, Katsumata K, Kato S, Satoh T, Ozeki M, Baba E, Yoshida S, Boku N, Hyodo I. Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV study). Med Oncol 2012;29:2842-8. [PMID: 22209842 DOI: 10.1007/s12032-011-0151-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
182 Grothey A, Allegra C. Antiangiogenesis therapy in the treatment of metastatic colorectal cancer. Ther Adv Med Oncol. 2012;4:301-319. [PMID: 23118806 DOI: 10.1177/1758834012454464] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
183 Lee J, Shin SJ, Chung IJ, Kim TW, Chun HG, Shin DB, Kim YH, Song HS, Han SW, Kim JG, Kim SY, Choi YJ, Chung HC. A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancer. Invest New Drugs 2014;32:561-8. [PMID: 24573743 DOI: 10.1007/s10637-014-0075-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
184 Huang M, Kan J, Ma C, Huang C, Chen F, Chuang C, Chan H, Huang C, Chang S, Wen Y, Wang J. An observational study of bevacizumab combined with FOLFIRI as the first-line treatment in metastatic colorectal cancer. Genomic Medicine, Biomarkers, and Health Sciences 2012;4:122-7. [DOI: 10.1016/j.gmbhs.2013.02.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
185 Shahda S, Saif MW. Regorafenib: from bench to bedside in colorectal cancer. Expert Rev Clin Pharmacol 2013;6:243-8. [PMID: 23656338 DOI: 10.1586/ecp.13.11] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
186 Ortega J, Vigil CE, Chodkiewicz C. Current Progress in Targeted Therapy for Colorectal Cancer. Cancer Control 2010;17:7-15. [DOI: 10.1177/107327481001700102] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 2.8] [Reference Citation Analysis]
187 Bong JW, Lee JL, Kim CW, Yoon YS, Park IJ, Lim SB, Yu CS, Kim TW, Kim JC. Risk Factors and Adequate Management for Complications of Bevacizumab Treatment Requiring Surgical Intervention in Patients With Metastatic Colorectal Cancer. Clin Colorectal Cancer. 2018;17:e639-e645. [PMID: 30031634 DOI: 10.1016/j.clcc.2018.06.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
188 Wang F, Dai G, Deng Y, Tang Y, Wang W, Niu Z, Bi F, Zhu L, Guo Z, Yan J, Hu B, Tao M, Yang S, Zhang S, Wen L, Xu R. Efficacy and safety of chemotherapy combined with bevacizumab in Chinese patients with metastatic colorectal cancer: A prospective, multicenter, observational, non-interventional phase IV trial. Chin J Cancer Res 2021;33:490-9. [PMID: 34584374 DOI: 10.21147/j.issn.1000-9604.2021.04.06] [Reference Citation Analysis]
189 Higuchi A, Aoyama T, Kazama K, Murakawa M, Atsumi Y, Katayama Y, Numata K, Sawazaki S, Numata M, Sato S, Sugano N, Tamagawa H, Mushiake H, Oshima T, Yukawa N, Morinaga S, Rino Y, Masuda M, Shiozawa M. Beppu's Nomogram Score Is an Independent Prognostic Factor for Colorectal Liver Metastasis Receiving Perioperative Chemotherapy and/or Targeted Therapy. In Vivo 2019;33:1301-6. [PMID: 31280222 DOI: 10.21873/invivo.11603] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
190 Chen H, Lin J, Chen J, Chuang C, Liu M, Wang J, Changchien C. Neoadjuvant therapy of bevacizumab in combination with oxaliplatin and capecitabine (XELOX) for patients with metastatic colorectal cancer with unresectable liver metastases: a phase II, open-label, single-arm, noncomparative trial. Asia-Pac J Clin Oncol 2018;14:61-8. [DOI: 10.1111/ajco.12692] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
191 Jenab-Wolcott J, Giantonio BJ. Antiangiogenic therapy in colorectal cancer: where are we 5 years later? Clin Colorectal Cancer 2010;9 Suppl 1:S7-15. [PMID: 20630853 DOI: 10.3816/CCC.2010.s.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
192 Hong YS, Kim TW. Chemotherapy for Colorectal Cancer. Korean J Gastroenterol 2009;54:355. [DOI: 10.4166/kjg.2009.54.6.355] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
193 Bergamo A, Sava G. Linking the future of anticancer metal-complexes to the therapy of tumour metastases. Chem Soc Rev 2015;44:8818-35. [DOI: 10.1039/c5cs00134j] [Cited by in Crossref: 142] [Cited by in F6Publishing: 22] [Article Influence: 20.3] [Reference Citation Analysis]
194 Cheon E, Small W, Strouch M, Krantz S, Rademaker A, Mulcahy M, Benson A, Bentrem D, Talamonti M. The effects of bevacizumab on postoperative complications in patients undergoing colorectal and pancreatic cancer resection. J Surg Oncol 2010;102:539-42. [DOI: 10.1002/jso.21598] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
195 Bose D, Meric-Bernstam F, Hofstetter W, Reardon DA, Flaherty KT, Ellis LM. Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care. Lancet Oncol. 2010;11:373-382. [PMID: 20171141 DOI: 10.1016/s1470-2045(09)70341-9] [Cited by in Crossref: 85] [Cited by in F6Publishing: 38] [Article Influence: 7.1] [Reference Citation Analysis]
196 Dai S, Ye Y, Kong X, Li J, Ding K. A predictive model for early recurrence of colorectal-cancer liver metastases based on clinical parameters. Gastroenterol Rep (Oxf) 2021;9:241-51. [PMID: 34316374 DOI: 10.1093/gastro/goaa092] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
197 Bendell JC, Bekaii-Saab TS, Cohn AL, Hurwitz HI, Kozloff M, Tezcan H, Roach N, Mun Y, Fish S, Flick ED, Dalal D, Grothey A. Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study. Oncologist 2012;17:1486-95. [PMID: 23015662 DOI: 10.1634/theoncologist.2012-0190] [Cited by in Crossref: 65] [Cited by in F6Publishing: 63] [Article Influence: 6.5] [Reference Citation Analysis]
198 Hornberger J, Degtiar I, Gutierrez H, Shewade A, Henner WD, Becker S, Varadhachary G, Raab S. Cost-effectiveness of gene-expression profiling for tumor-site origin. Value Health 2013;16:46-56. [PMID: 23337215 DOI: 10.1016/j.jval.2012.09.005] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
199 Lin Q, Ye Q, Zhu D, Wei Y, Ren L, Zheng P, Xu P, Ye L, Lv M, Fan J, Xu J. Comparison of minimally invasive and open colorectal resections for patients undergoing simultaneous R0 resection for liver metastases: a propensity score analysis. Int J Colorectal Dis. 2015;30:385-395. [PMID: 25503803 DOI: 10.1007/s00384-014-2089-2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
200 Okuno M, Hatano E, Seo S, Taura K, Yasuchika K, Nakajima A, Yazawa T, Furuyama H, Kawamoto H, Yagi S. Indication for neoadjuvant chemotherapy in patients with colorectal liver metastases based on a nomogram that predicts disease-free survival. J Hepatobiliary Pancreat Sci. 2014;21:881-888. [PMID: 25155418 DOI: 10.1002/jhbp.149] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
201 Hong YS, Kim JH, Kim TW. Treatment Strategy for Elderly Patients with Metastatic Colorectal Cancer: A Review of the Systemic Chemotherapy Options. Curr Colorectal Cancer Rep 2013;9:213-22. [DOI: 10.1007/s11888-013-0172-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
202 Tahover E, Uziely B, Salah A, Temper M, Peretz T, Hubert A. Hypertension as a predictive biomarker in bevacizumab treatment for colorectal cancer patients. Med Oncol 2013;30:327. [PMID: 23254964 DOI: 10.1007/s12032-012-0327-4] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 2.9] [Reference Citation Analysis]
203 Fiorentini G, Sarti D, Aliberti C, Carandina R, Mambrini A, Guadagni S. Multidisciplinary approach of colorectal cancer liver metastases. World J Clin Oncol 2017; 8(3): 190-202 [PMID: 28638789 DOI: 10.5306/wjco.v8.i3.190] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 24] [Article Influence: 5.6] [Reference Citation Analysis]
204 De Stefano A, Carlomagno C, Pepe S, Bianco R, De Placido S. Bevacizumab-related arterial hypertension as a predictive marker in metastatic colorectal cancer patients. Cancer Chemother Pharmacol. 2011;68:1207-1213. [PMID: 21409384 DOI: 10.1007/s00280-011-1604-1] [Cited by in Crossref: 51] [Cited by in F6Publishing: 50] [Article Influence: 4.6] [Reference Citation Analysis]
205 Lee B, Wong HL, Tacey M, Tie J, Wong R, Lee M, Nott L, Shapiro J, Jennens R, Turner N, Tran B, Ananda S, Yip D, Richardson G, Parente P, Lim L, Stefanou G, Burge M, Iddawela M, Power J, Gibbs P. The impact of bevacizumab in metastatic colorectal cancer with an intact primary tumor: Results from a large prospective cohort study. Asia Pac J Clin Oncol 2017;13:314-21. [PMID: 27885818 DOI: 10.1111/ajco.12639] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
206 Osterlund P, Peltonen R, Alanko T, Bono P, Isoniemi H. A single-institution experience with bevacizumab in the treatment of metastatic colorectal cancer and in conjunction with liver resection. Onco Targets Ther. 2014;7:1177-1184. [PMID: 25061319 DOI: 10.2147/ott.s63739] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
207 Date E, Okamoto K, Fumita S, Kaneda H. Gastrointestinal perforation related to lenvatinib, an anti-angiogenic inhibitor that targets multiple receptor tyrosine kinases, in a patient with metastatic thyroid cancer. Invest New Drugs 2018;36:350-3. [PMID: 29018997 DOI: 10.1007/s10637-017-0522-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
208 O'Hare T, McDermott R, Hannon R. Late anastomotic breakdown with bevacizumab in colorectal cancers, a case-based review. Ir J Med Sci 2018;187:333-6. [PMID: 28852961 DOI: 10.1007/s11845-017-1676-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
209 Fiala O, Pitule P, Hosek P, Liska V, Sorejs O, Bruha J, Vycital O, Buchler T, Poprach A, Topolcan O, Finek J. The association of miR-126-3p, miR-126-5p and miR-664-3p expression profiles with outcomes of patients with metastatic colorectal cancer treated with bevacizumab. Tumour Biol 2017;39:1010428317709283. [PMID: 28714375 DOI: 10.1177/1010428317709283] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
210 Metges JP, Lebot MA, Faroux R, Riaud F, Gamelin E, Capitain O, Guérin Meyer V, Leynia P, Douillard JY, Senellart H, Rochard S, Louvigné C, Campion L, Dupuis O, Grollier C, Achour NA, Person B, Raoul JL, Boucher E, Bertrand C, Ramée JF, Guivarch L, Etienne PL, Roussel S, Desclos H, Julien MN, Labarre MI, Klein V, Bessard R, Stampfli C, Royet F, Faycal J, Gouva S, Le Bihan G, Couturier M, Gourlaouen A, Bertholom C, Porneuf M, Jobard E, Peguet E, Grasset D, Bouret JF, Bicheler V, Ulvoas A, Miglianico L, Chouzenoux C, Deguiral P, Derenne L, Martin D, Langlet PM, Bodin C, Rossi V, Barré S, Cojocarasu O, Naveau Ploux C, Vidal AM, Cumin I, Egreteau J, Brouard A, Matysiak Budnik T, Thomaré P, Le Bris Michel AS, Piriou G, Largeau R, Elhannani C, Crespeau E, Suberville F, Bourgeois H, Riche C, Lagadec DD, Marhuenda F, Grudé F. Evaluation in usual practice of the bevacizumab-FOLFIRI combination for the first-line treatment of patients with unresectable metastatic colorectal cancer treated in 2006: focus on resected patients and oncogeriatrics: AVASTIN OUEST cohort of the Observatory of Cancer of the Brittany and Pays de la Loire Areas (Observatoire dédié au Cancer Bretagne / Pays de la Loire). Oncologie (Paris) 2014;16:267-76. [PMID: 26190928 DOI: 10.1007/s10269-014-2391-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
211 Leite de Oliveira R, Hamm A, Mazzone M. Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies. Mol Aspects Med 2011;32:71-87. [PMID: 21540050 DOI: 10.1016/j.mam.2011.04.001] [Cited by in Crossref: 68] [Cited by in F6Publishing: 64] [Article Influence: 6.2] [Reference Citation Analysis]
212 Wanebo HJ, Berz D. The neoadjuvant therapy of colorectal hepatic metastases and the role of biologic sensitizing and resistance factors. J Surg Oncol 2010;102:891-7. [PMID: 21165990 DOI: 10.1002/jso.21691] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
213 Baxter NN, Fischer HD, Richardson DP, Urbach DR, Bell CM, Rochon P, Brade A, Earle CC. A Population-Based Study of Complications After Colorectal Surgery in Patients Who Have Received Bevacizumab. Dis Colon Rectum 2018;61:306-13. [PMID: 29420426 DOI: 10.1097/DCR.0000000000000966] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
214 Cai J, Ma H, Huang F, Zhu D, Bi J, Ke Y, Zhang T. Correlation of bevacizumab-induced hypertension and outcomes of metastatic colorectal cancer patients treated with bevacizumab: a systematic review and meta-analysis. World J Surg Oncol 2013;11:306. [PMID: 24283603 DOI: 10.1186/1477-7819-11-306] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 4.7] [Reference Citation Analysis]
215 Fiala O, Finek J, Buchler T, Matejka VM, Holubec L, Kulhankova J, Bortlicek Z, Liska V, Topolcan O. The Association of Serum Carcinoembryonic Antigen, Carbohydrate Antigen 19-9, Thymidine Kinase, and Tissue Polypeptide Specific Antigen with Outcomes of Patients with Metastatic Colorectal Cancer Treated with Bevacizumab: a Retrospective Study. Target Oncol 2015;10:549-55. [PMID: 25875421 DOI: 10.1007/s11523-015-0365-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
216 Ma H, Wu X, Tao M, Tang N, Li Y, Zhang X, Zhou Q. Efficacy and safety of bevacizumab-based maintenance therapy in metastatic colorectal cancer: A meta-analysis. Medicine (Baltimore) 2019;98:e18227. [PMID: 31852082 DOI: 10.1097/MD.0000000000018227] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
217 Strickler JH, Hurwitz HI. Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer. Oncologist. 2012;17:513-524. [PMID: 22477726 DOI: 10.1634/theoncologist.2012-0003] [Cited by in Crossref: 48] [Cited by in F6Publishing: 39] [Article Influence: 4.8] [Reference Citation Analysis]
218 Lenk L, Pein M, Will O, Gomez B, Viol F, Hauser C, Egberts JH, Gundlach JP, Helm O, Tiwari S, Weiskirchen R, Rose-John S, Röcken C, Mikulits W, Wenzel P, Schneider G, Saur D, Schäfer H, Sebens S. The hepatic microenvironment essentially determines tumor cell dormancy and metastatic outgrowth of pancreatic ductal adenocarcinoma. Oncoimmunology 2017;7:e1368603. [PMID: 29296518 DOI: 10.1080/2162402X.2017.1368603] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
219 Bruera G, Cannita K, Giuliante F, Baldi PL, Vicentini R, Marchetti P, Nuzzo G, Antonucci A, Ficorella C, Ricevuto E. Effectiveness of Liver Metastasectomies in Patients With Metastatic Colorectal Cancer Treated With FIr-B/FOx Triplet Chemotherapy Plus Bevacizumab. Clinical Colorectal Cancer 2012;11:119-26. [DOI: 10.1016/j.clcc.2011.11.002] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
220 Capitain O, Asevoaia A, Boisdron-Celle M, Poirier AL, Morel A, Gamelin E. Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study. Clin Colorectal Cancer. 2012;11:263-267. [PMID: 22683364 DOI: 10.1016/j.clcc.2012.05.004] [Cited by in Crossref: 57] [Cited by in F6Publishing: 53] [Article Influence: 5.7] [Reference Citation Analysis]
221 Akgül Ö, Çetinkaya E, Ersöz Ş, Tez M. Role of surgery in colorectal cancer liver metastases. World J Gastroenterol. 2014;20:6113-6122. [PMID: 24876733 DOI: 10.3748/wjg.v20.i20.6113.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
222 Masi G, Loupakis F, Salvatore L, Fornaro L, Cremolini C, Cupini S, Ciarlo A, Del Monte F, Cortesi E, Amoroso D. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol. 2010;11:845-852. [PMID: 20702138 DOI: 10.1016/s1470-2045(10)70175-3] [Cited by in Crossref: 186] [Cited by in F6Publishing: 91] [Article Influence: 15.5] [Reference Citation Analysis]
223 Raouf S, Bridgewater J, Ellis R, Ferry D, Hill M, Wasan H. Use of bevacizumab in the treatment of metastatic colorectal cancer. Br J Hosp Med (Lond) 2012;73:25-30. [PMID: 22241406 DOI: 10.12968/hmed.2012.73.1.25] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
224 Saito S, Hayashi N, Sato N, Iwatsuki M, Baba Y, Sakamoto Y, Miyamoto Y, Watanabe M, Yoshida M, Sakai K, Katsumori T, Katahuchi S, Shigaki N, Yamada K, Kimura M, Tanigawa T, Takano S, Kuramoto M, Baba H. Chemotherapy with bevacizumab for metastatic colorectal cancer: a retrospective review of 181 Japanese patients. Int J Clin Oncol 2013;18:689-95. [DOI: 10.1007/s10147-012-0426-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
225 Ikoma N, Rodriguez-bigas MA. Managing the Primary Tumor with Unresectable Synchronous Colorectal Metastases. Curr Colorectal Cancer Rep 2016;12:170-9. [DOI: 10.1007/s11888-016-0322-9] [Reference Citation Analysis]
226 Petrelli F, Borgonovo K, Cabiddu M, Ghilardi M, Lonati V, Maspero F, Sauta MG, Beretta GD, Barni S. FOLFIRI-bevacizumab as first-line chemotherapy in 3500 patients with advanced colorectal cancer: a pooled analysis of 29 published trials. Clin Colorectal Cancer. 2013;12:145-151. [PMID: 23763824 DOI: 10.1016/j.clcc.2013.04.006] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 4.3] [Reference Citation Analysis]
227 Lee YC, Michael M, Zalcberg JR. An overview of experimental and investigational multikinase inhibitors for the treatment of metastatic colorectal cancer. Expert Opinion on Investigational Drugs 2015;24:1307-20. [DOI: 10.1517/13543784.2015.1070483] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
228 Snoeren N, van Hillegersberg R, Schouten SB, Bergman AM, van Werkhoven E, Dalesio O, Tollenaar RA, Verheul HM, van der Sijp J, Borel Rinkes IH, Voest EE; Hepatica study group. Randomized Phase III Study to Assess Efficacy and Safety of Adjuvant CAPOX with or without Bevacizumab in Patients after Resection of Colorectal Liver Metastases: HEPATICA study. Neoplasia 2017;19:93-9. [PMID: 28088688 DOI: 10.1016/j.neo.2016.08.010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
229 Tamandl D, Gruenberger B, Klinger M, Herberger B, Kaczirek K, Fleischmann E, Gruenberger T. Liver resection remains a safe procedure after neoadjuvant chemotherapy including bevacizumab: a case-controlled study. Ann Surg. 2010;252:124-130. [PMID: 20562613 DOI: 10.1097/sla.0b013e3181deb67f] [Cited by in Crossref: 38] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
230 Hori N, Iwasa S, Hashimoto H, Yanai T, Kato K, Hamaguchi T, Yamada Y, Murakoshi K, Yokote N, Yamamoto H, Shimada Y. Reasons for avoidance of bevacizumab with first-line FOLFOX for advanced colorectal cancer. Int J Clin Oncol 2013;18:435-8. [PMID: 22415742 DOI: 10.1007/s10147-012-0398-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
231 Kato A, Shimizu H, Ohtsuka M, Yoshidome H, Yoshitomi H, Furukawa K, Takeuchi D, Takayashiki T, Kimura F, Miyazaki M. Surgical resection after downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer: a retrospective single-center study. Ann Surg Oncol. 2013;20:318-324. [PMID: 23149849 DOI: 10.1245/s10434-012-2312-8] [Cited by in Crossref: 75] [Cited by in F6Publishing: 64] [Article Influence: 7.5] [Reference Citation Analysis]
232 D'Agay MG, Galland L, Tharin Z, Truntzer C, Ghiringhelli F. Utility of exome sequencing in routine care for metastatic colorectal cancer. Mol Clin Oncol 2021;15:229. [PMID: 34631054 DOI: 10.3892/mco.2021.2392] [Reference Citation Analysis]
233 Tapia Rico G, Townsend AR, Broadbridge V, Price TJ. Targeted Therapies in Elderly Patients with Metastatic Colorectal Cancer: A Review of the Evidence. Drugs Aging 2017;34:173-89. [PMID: 28197947 DOI: 10.1007/s40266-017-0439-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
234 Suenaga M, Mizunuma N, Shinozaki E, Matsusaka S, Ozaka M, Ogura M, Chin K, Yamaguchi T. Anticoagulant therapy for venous thromboembolism detected by Doppler ultrasound in patients with metastatic colorectal cancer receiving bevacizumab. Onco Targets Ther 2015;8:243-9. [PMID: 25670906 DOI: 10.2147/OTT.S75722] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
235 Blumenthal DT, Mendel L, Bokstein F. The optimal regimen of bevacizumab for recurrent glioblastoma: does dose matter? J Neurooncol 2016;127:493-502. [PMID: 26721244 DOI: 10.1007/s11060-015-2025-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
236 Cotte E, Villeneuve L, Passot G, Boschetti G, Bin-Dorel S, Francois Y, Glehen O; French Research Group of Rectal Cancer Surgery (GRECCAR). GRECCAR 8: impact on survival of the primary tumor resection in rectal cancer with unresectable synchronous metastasis: a randomized multicentre study. BMC Cancer 2015;15:47. [PMID: 25849254 DOI: 10.1186/s12885-015-1060-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
237 Kabbinavar F, Kozloff M. Regarding ‘Treatment of Colorectal Cancer with and without Bevacizumab: A Phase III Study’. Oncology 2011;80:135-7. [DOI: 10.1159/000327227] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
238 Yalcin S, Uslu R, Dane F, Yilmaz U, Zengin N, Buyukunal E, Buyukberber S, Camci C, Sencan O, Kilickap S. Bevacizumab + capecitabine as maintenance therapy after initial bevacizumab + XELOX treatment in previously untreated patients with metastatic colorectal cancer: phase III 'Stop and Go' study results--a Turkish Oncology Group Trial. Oncology. 2013;85:328-335. [PMID: 24247559 DOI: 10.1159/000355914] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 4.9] [Reference Citation Analysis]
239 Barone M, Prioletta M, Di Nuzzo D, Cipollone G, Camplese P, Mucilli F. Pulmonary metastasectomy in elderly colorectal cancer patients: a retrospective single center study. Updates Surg 2016;68:357-67. [DOI: 10.1007/s13304-016-0399-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
240 Gherman A, Căinap C, Constantin AM, Cetean S, Căinap SS. Molecular targeted treatment of metastatic colorectal cancer: the cardiovascular adverse effects of Bevacizumab and Cetuximab. Clujul Med 2017;90:377-84. [PMID: 29151784 DOI: 10.15386/cjmed-745] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
241 Ishii Y, Hasegawa H, Endo T, Okabayashi K, Ochiai H, Moritani K, Watanabe M, Kitagawa Y. Medium-term results of neoadjuvant systemic chemotherapy using irinotecan, 5-fluorouracil, and leucovorin in patients with locally advanced rectal cancer. Eur J Surg Oncol. 2010;36:1061-1065. [PMID: 20538422 DOI: 10.1016/j.ejso.2010.05.017] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 3.9] [Reference Citation Analysis]
242 Kanat O. Current treatment options for patients with initially unresectable isolated colorectal liver metastases. World J Clin Oncol 2016; 7(1): 9-14 [PMID: 26862487 DOI: 10.5306/wjco.v7.i1.9] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
243 Zhao L, Li W, Zhang H, Hou N, Guo L, Gao Q. Angiogenesis inhibitors rechallenge in patients with advanced non-small-cell lung cancer: a pooled analysis of randomized controlled trials. Onco Targets Ther 2015;8:2775-81. [PMID: 26491352 DOI: 10.2147/OTT.S88102] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
244 Borzomati D, Nappo G, Valeri S, Vincenzi B, Ripetti V, Coppola R. Infusion of Bevacizumab increases the risk of intestinal perforation: results on a series of 143 patients consecutively treated. Updates Surg 2013;65:121-4. [DOI: 10.1007/s13304-013-0207-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
245 Cortés J, Caralt M, Delaloge S, Cortes-Funes H, Pierga JY, Pritchard KI, Bollag DT, Miles DW. Safety of bevacizumab in metastatic breast cancer patients undergoing surgery. Eur J Cancer 2012;48:475-81. [PMID: 22196033 DOI: 10.1016/j.ejca.2011.11.021] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
246 Wong NS, Fernando NH, Bendell JC, Morse MA, Blobe GC, Honeycutt W, Pang H, Hurwitz HI. A phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer. Clin Colorectal Cancer 2011;10:210-6. [PMID: 21855046 DOI: 10.1016/j.clcc.2011.03.018] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
247 Massarweh NN, Li LT, Sansgiry S, Berger DH, Anaya DA. Primary Tumor Resection and Multimodality Treatment for Patients with Metastatic Colon Cancer. Ann Surg Oncol 2016;23:1815-23. [DOI: 10.1245/s10434-015-5073-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
248 Mccleary NJ, Dotan E, Browner I. Refining the Chemotherapy Approach for Older Patients With Colon Cancer. JCO 2014;32:2570-80. [DOI: 10.1200/jco.2014.55.1960] [Cited by in Crossref: 33] [Cited by in F6Publishing: 14] [Article Influence: 4.1] [Reference Citation Analysis]
249 Field K, Wong HL, Shapiro J, Kosmider S, Tie J, Bae S, Yip D, McKendrick J, Nott L, Desai J. Developing a national database for metastatic colorectal cancer management: perspectives and challenges. Intern Med J. 2013;43:1224-1231. [PMID: 23834128 DOI: 10.1111/imj.12230] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
250 Bai L, Wang F, Li ZZ, Ren C, Zhang DS, Zhao Q, Lu YX, Wang DS, Ju HQ, Qiu MZ, Wang ZQ, Wang FH, Xu RH. Chemotherapy plus bevacizumab versus chemotherapy plus cetuximab as first-line treatment for patients with metastatic colorectal cancer: Results of a registry-based cohort analysis. Medicine (Baltimore) 2016;95:e4531. [PMID: 28002313 DOI: 10.1097/MD.0000000000004531] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
251 Zoratto F, Rossi L, Zullo A, Papa A, Zaccarelli E, Tomao L, Giordani E, Colonna M, Baiano G, Tomao S. Critical appraisal of bevacizumab in the treatment of metastatic colorectal cancer. Onco Targets Ther 2012;5:199-211. [PMID: 23055745 DOI: 10.2147/OTT.S30581] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
252 Moth EB, Vardy J, Blinman P. Decision-making in geriatric oncology: systemic treatment considerations for older adults with colon cancer. Expert Rev Gastroenterol Hepatol 2016;10:1321-40. [PMID: 27718755 DOI: 10.1080/17474124.2016.1244003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
253 Garant A, Des Groseilliers S, Martin L, Ferland É, Vuong T. Late Anastomotic Dehiscence during Bevacizumab Therapy for Patients with Colorectal Cancer. Clinical Oncology 2011;23:497-8. [DOI: 10.1016/j.clon.2011.03.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
254 Maleux G, Vaninbroukx J, Heye S, van Cutsem E, Oyen R. Aneurysm formation in an angiomyolipoma during bevacizumab combination therapy. Acta Oncol 2010;49:864-6. [PMID: 20230212 DOI: 10.3109/02841861003649257] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
255 Loupakis F, Bria E, Vaccaro V, Cuppone F, Milella M, Carlini P, Cremolini C, Salvatore L, Falcone A, Muti P. Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials. J Exp Clin Cancer Res. 2010;29:58. [PMID: 20504361 DOI: 10.1186/1756-9966-29-58] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 3.3] [Reference Citation Analysis]
256 Aprile G, Fontanella C, Lutrino ES, Ferrari L, Casagrande M, Cardellino GG, Rosati G, Fasola G. Angiogenic inhibitors for older patients with advanced colorectal cancer: Does the age hold the stage? World J Gastroenterol 2013; 19(14): 2131-2140 [PMID: 23847406 DOI: 10.3748/wjg.v19.i14.2131] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
257 Recondo GJ, Díaz-Cantón E, de la Vega M, Greco M, Recondo GS, Valsecchi ME. Advances and new perspectives in the treatment of metastatic colon cancer. World J Gastrointest Oncol 2014; 6(7): 211-224 [PMID: 25024813 DOI: 10.4251/wjgo.v6.i7.211] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
258 Lin Q, Ye Q, Zhu D, Wei Y, Ren L, Ye L, Feng Q, Xu P, Zheng P, Lv M, Fan J, Xu J. Determinants of long-term outcome in patients undergoing simultaneous resection of synchronous colorectal liver metastases. PLoS One 2014;9:e105747. [PMID: 25162714 DOI: 10.1371/journal.pone.0105747] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
259 Di Bartolomeo M, Pietrantonio F, Martinetti A, Buzzoni R, Gevorgyan A, Bajetta E. Role of the antiangiogenic agent bevacizumab in the treatment of elderly patients with metastatic colorectal cancer. Drugs Aging 2011;28:83-91. [PMID: 21155618 DOI: 10.2165/11584710-000000000-00000] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
260 Renouf DJ, Lim HJ, Speers C, Villa D, Gill S, Blanke CD, O'Reilly SE, Kennecke H. Survival for metastatic colorectal cancer in the bevacizumab era: a population-based analysis. Clin Colorectal Cancer 2011;10:97-101. [PMID: 21859560 DOI: 10.1016/j.clcc.2011.03.004] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
261 Beca JM, Dai WF, Pataky RE, Tran D, Dvorani E, Isaranuwatchai W, Peacock S, Alvi R, Cheung WY, Earle CC, Gavura S, Chan KKW. Real-world Safety of Bevacizumab with First-line Combination Chemotherapy in Patients with Metastatic Colorectal Cancer: Population-based Retrospective Cohort Studies in Three Canadian Provinces. Clin Oncol (R Coll Radiol) 2021:S0936-6555(21)00295-8. [PMID: 34456106 DOI: 10.1016/j.clon.2021.08.009] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
262 Wu D, Zhao Y, Fu S, Zhang J, Wang W, Yan Z, Guo H, Liu A. Seleno-short-chain chitosan induces apoptosis in human breast cancer cells through mitochondrial apoptosis pathway in vitro. Cell Cycle 2018;17:1579-90. [PMID: 29895197 DOI: 10.1080/15384101.2018.1464845] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
263 Lam VW, Spiro C, Laurence JM, Johnston E, Hollands MJ, Pleass HC, Richardson AJ. A systematic review of clinical response and survival outcomes of downsizing systemic chemotherapy and rescue liver surgery in patients with initially unresectable colorectal liver metastases. Ann Surg Oncol. 2012;19:1292-1301. [PMID: 21922338 DOI: 10.1245/s10434-011-2061-0] [Cited by in Crossref: 110] [Cited by in F6Publishing: 99] [Article Influence: 10.0] [Reference Citation Analysis]
264 Nasti G, Piccirillo MC, Izzo F, Ottaiano A, Albino V, Delrio P, Romano C, Giordano P, Lastoria S, Caracò C. Neoadjuvant FOLFIRI+bevacizumab in patients with resectable liver metastases from colorectal cancer: a phase 2 trial. Br J Cancer. 2013;108:1566-1570. [PMID: 23558891 DOI: 10.1038/bjc.2013.140] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 3.2] [Reference Citation Analysis]
265 Mima K, Beppu T, Chikamoto A, Miyamoto Y, Nakagawa S, Kuroki H, Okabe H, Hayashi H, Sakamoto Y, Watanabe M, Kikuchi K, Baba H. Hepatic resection combined with radiofrequency ablation for initially unresectable colorectal liver metastases after effective chemotherapy is a safe procedure with a low incidence of local recurrence. Int J Clin Oncol 2013;18:847-55. [DOI: 10.1007/s10147-012-0471-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
266 Ewara EM, Zaric GS, Welch S, Sarma S. Cost-effectiveness of first-line treatments for patients with KRAS wild-type metastatic colorectal cancer. Curr Oncol 2014;21:e541-50. [PMID: 25089105 DOI: 10.3747/co.21.1837] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
267 Sun DC, Shi Y, Wang YR, Lv Y, Yan H, Mao H, Wang ZK, Wu ZY, Shi WW, Dai GH. KRAS mutation and primary tumor location do not affect efficacy of bevacizumab-containing chemotherapy in stagae IV colorectal cancer patients. Sci Rep 2017;7:14368. [PMID: 29085005 DOI: 10.1038/s41598-017-14669-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
268 Li S, Chi P. Optimizing the efficacy of first-line chemotherapy plus bevacizumab in metastatic colorectal cancer: analysis of multiple methods. BioDrugs 2011;25:43-50. [PMID: 21080747 DOI: 10.2165/11584680-000000000-00000] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
269 Ribecco AS, Pino MS, Cipriani G, Marinozzi C, Fioretto L. Molecularly targeted therapy: toxicity and quality of life considerations in advanced colorectal cancer. Expert Review of Anticancer Therapy 2014;13:1181-91. [DOI: 10.1586/14737140.2013.837667] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
270 Smith I, Pierga J, Biganzoli L, Cortés-funes H, Thomssen C, Pivot X, Fabi A, Xu B, Stroyakovskiy D, Franke F, Kaufman B, Mainwaring P, Pienkowski T, De Valk B, Kwong A, González-trujillo J, Koza I, Petrakova K, Pereira D, Pritchard K. First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2251 patients. Annals of Oncology 2011;22:595-602. [DOI: 10.1093/annonc/mdq430] [Cited by in Crossref: 70] [Cited by in F6Publishing: 70] [Article Influence: 6.4] [Reference Citation Analysis]
271 Elamin YY, Rafee S, Toomey S, Hennessy BT. Immune effects of bevacizumab: killing two birds with one stone. Cancer Microenviron. 2015;8:15-21. [PMID: 25326055 DOI: 10.1007/s12307-014-0160-8] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 4.3] [Reference Citation Analysis]
272 Hompes D, Ruers T. Review: incidence and clinical significance of Bevacizumab-related non-surgical and surgical serious adverse events in metastatic colorectal cancer. Eur J Surg Oncol 2011;37:737-46. [PMID: 21764243 DOI: 10.1016/j.ejso.2011.06.004] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 3.5] [Reference Citation Analysis]
273 Arance AM, Berrocal A, Lopez-martin JA, de la Cruz-merino L, Soriano V, Martín Algarra S, Alonso L, Cerezuela P, La Orden B, Espinosa E. Safety of vemurafenib in patients with BRAF V600 mutated metastatic melanoma: the Spanish experience. Clin Transl Oncol 2016;18:1147-57. [DOI: 10.1007/s12094-016-1498-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
274 Bouché O, Beretta GD, Alfonso PG, Geissler M. The role of anti-epidermal growth factor receptor monoclonal antibody monotherapy in the treatment of metastatic colorectal cancer. Cancer Treatment Reviews 2010;36:S1-S10. [DOI: 10.1016/s0305-7372(10)00036-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
275 Lee EK, Revil C, Ngoh CA, Lister J, Kwon JM, Park MH, Park SJ, Park YS, Shin SJ, Lee MA, Lee NS, Zang DY, Bae EJ, Kang MJ. Clinical and cost effectiveness of bevacizumab + FOLFIRI combination versus FOLFIRI alone as first-line treatment of metastatic colorectal cancer in South Korea. Clin Ther 2012;34:1408-19. [PMID: 22657254 DOI: 10.1016/j.clinthera.2012.05.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
276 Liu J, Fan L, Wang H, Sun G. Autophagy, a double-edged sword in anti-angiogenesis therapy. Med Oncol 2016;33:10. [PMID: 26715036 DOI: 10.1007/s12032-015-0721-9] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 5.3] [Reference Citation Analysis]
277 Mccleary NJ, Harmsen WS, Haakenstad E, Cleary JM, Meyerhardt JA, Zalcberg J, Adams R, Grothey A, Sobrero AF, Van Cutsem E, Goldberg RM, Peeters M, Tabernero J, Seymour M, Saltz LB, Giantonio BJ, Arnold D, Rothenberg ML, Koopman M, Schmoll H, Pitot HC, Hoff PM, Tebbutt N, Masi G, Souglakos J, Bokemeyer C, Heinemann V, Yoshino T, Chibaudel B, deGramont A, Shi Q, Lichtman SM. Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials. JNCI Cancer Spectrum 2022;6:pkac014. [DOI: 10.1093/jncics/pkac014] [Reference Citation Analysis]
278 Nordlinger B, Adam R, Arnold D, Zalcberg JR, Gruenberger T. The role of biological agents in the resection of colorectal liver metastases. Clin Oncol (R Coll Radiol). 2012;24:432-442. [PMID: 22794325 DOI: 10.1016/j.clon.2012.01.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
279 Yamamoto T, Uemura K, Moriyama K, Mitamura K, Taga A. Inhibitory effect of maple syrup on the cell growth and invasion of human colorectal cancer cells. Oncol Rep 2015;33:1579-84. [PMID: 25647359 DOI: 10.3892/or.2015.3777] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
280 Cima RR. Surgical Outcomes in Inflammatory Bowel Disease Patients and the Potential Impact of Biologic Therapies. Seminars in Colon and Rectal Surgery 2012;23:89-93. [DOI: 10.1053/j.scrs.2012.02.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
281 Ohhara Y, Suenaga M, Matsusaka S, Shinozaki E, Mizunuma N, Yamaguchi T. Comparison between three oxaliplatin-based regimens with bevacizumab in patients with metastatic colorectal cancer. Onco Targets Ther. 2015;8:529-537. [PMID: 25767397 DOI: 10.2147/ott.s77190] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
282 Petrelli F, Borgonovo K, Cabiddu M, Ghilardi M, Barni S. Cetuximab and panitumumab in KRAS wild-type colorectal cancer: a meta-analysis. Int J Colorectal Dis. 2011;26:823-833. [PMID: 21286919 DOI: 10.1007/s00384-011-1149-0] [Cited by in Crossref: 41] [Cited by in F6Publishing: 45] [Article Influence: 3.7] [Reference Citation Analysis]
283 Matikas A, Asimakopoulou N, Georgoulias V, Souglakos J. The place of targeted agents in the treatment of elderly patients with metastatic colorectal cancer. Cancers (Basel) 2015;7:439-49. [PMID: 25782007 DOI: 10.3390/cancers7010439] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
284 Bennouna J, Phelip JM, Andre T, Asselain B, Kone S, Ducreux M. Observational cohort study of patients with metastasic colorectal cancer initiating chemothetaoy in combination with bevacizumab (CONCERT). Clin Colorectal Cancer. 2017;16:129-140. [PMID: 28277294 DOI: 10.1016/j.clcc.2016.07.013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
285 Di Bartolomeo M, Maggi C, Ricchini F, Pietrantonio F, Iacovelli R, de Braud F, Inno A. Bevacizumab treatment in the elderly patient with metastatic colorectal cancer. Clin Interv Aging 2015;10:127-33. [PMID: 25584021 DOI: 10.2147/CIA.S54675] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
286 Tapia Rico G, Klevansky M, Townsend A, Price T. Synovial metastasis of the knee in a KRAS mutant rectal adenocarcinoma patient. BMJ Case Rep 2017;2017:bcr-2017-220008. [PMID: 28784880 DOI: 10.1136/bcr-2017-220008] [Reference Citation Analysis]
287 Tahover E, Hubert A, Temper M, Salah A, Peretz T, Hamburger T, Uziely B. An observational cohort study of bevacizumab and chemotherapy in metastatic colorectal cancer patients: safety and efficacy with analysis by age group. Targ Oncol 2015;10:55-63. [DOI: 10.1007/s11523-014-0311-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
288 Takakura Y, Okajima M, Kanemitsu Y, Kuroda S, Egi H, Hinoi T, Tashiro H, Ohdan H. External validation of two nomograms for predicting patient survival after hepatic resection for metastatic colorectal cancer. World J Surg. 2011;35:2275-2282. [PMID: 21773952 DOI: 10.1007/s00268-011-1194-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
289 Schwandt A, von Gruenigen VE, Wenham RM, Frasure H, Eaton S, Fusco N, Fu P, Wright JJ, Dowlati A, Waggoner S. Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer. Invest New Drugs 2014;32:729-38. [PMID: 24619298 DOI: 10.1007/s10637-014-0078-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
290 Gao H, Song X, Kang T, Yan B, Feng L, Gao L, Ai L, Liu X, Yu J, Li H. Long noncoding RNA CRNDE functions as a competing endogenous RNA to promote metastasis and oxaliplatin resistance by sponging miR-136 in colorectal cancer. Onco Targets Ther. 2017;10:205-216. [PMID: 28115855 DOI: 10.2147/ott.s116178] [Cited by in Crossref: 46] [Cited by in F6Publishing: 26] [Article Influence: 9.2] [Reference Citation Analysis]
291 Khakoo S, Chau I, Pedley I, Ellis R, Steward W, Harrison M, Baijal S, Tahir S, Ross P, Raouf S, Ograbek A, Cunningham D; ACORN investigators. ACORN: Observational Study of Bevacizumab in Combination With First-Line Chemotherapy for Treatment of Metastatic Colorectal Cancer in the UK. Clin Colorectal Cancer 2019;18:280-291.e5. [PMID: 31451367 DOI: 10.1016/j.clcc.2019.07.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
292 Lindsay CR, Cassidy J. XELOX in colorectal cancer: a convenient option for the future? Expert Review of Gastroenterology & Hepatology 2014;5:9-19. [DOI: 10.1586/egh.10.90] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
293 Bruera G, Cannita K, Giordano AV, Vicentini R, Ficorella C, Ricevuto E. Prognostic relevance of KRAS genotype in metastatic colorectal cancer patients unfit for FIr-B/FOx intensive regimen. Int J Oncol 2014;44:1820-30. [PMID: 24715238 DOI: 10.3892/ijo.2014.2369] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
294 Tebbutt N, Kotasek D, Burris HA, Schwartzberg LS, Hurwitz H, Stephenson J, Warner DJ, Chen L, Hsu CP, Goldstein D. Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer. Cancer Chemother Pharmacol 2015;75:993-1004. [PMID: 25772756 DOI: 10.1007/s00280-015-2694-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
295 Yamada Y, Yamaguchi T, Matsumoto H, Ichikawa Y, Goto A, Kato K, Hamaguchi T, Shimada Y. Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB) as first-line therapy for patients with metastatic colorectal cancer. Invest New Drugs 2012;30:1690-6. [PMID: 21894500 DOI: 10.1007/s10637-011-9743-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
296 Varol U, Yildiz I, Salman T, Karabulut B, Uslu R. Markers to Predict the Efficacy of Bevacizumab in the Treatment of Metastatic Colorectal Cancer. Tumori Journal 2018;100:370-6. [DOI: 10.1177/1636.17888] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
297 Chevreau C, Méjean A, Pocard M. [Managing side-effects of targeted therapies in renal cancer:surgical complications]. Bull Cancer 2011;98:S61-7. [PMID: 25819127 DOI: 10.1684/bdc.2011.1442] [Reference Citation Analysis]
298 Díaz-Rubio E, Gómez-España A, Massutí B, Sastre J, Abad A, Valladares M, Rivera F, Safont MJ, Martínez de Prado P, Gallén M, González E, Marcuello E, Benavides M, Fernández-Martos C, Losa F, Escudero P, Arrivi A, Cervantes A, Dueñas R, López-Ladrón A, Lacasta A, Llanos M, Tabernero JM, Antón A, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumors. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study. Oncologist 2012;17:15-25. [PMID: 22234633 DOI: 10.1634/theoncologist.2011-0249] [Cited by in Crossref: 147] [Cited by in F6Publishing: 136] [Article Influence: 14.7] [Reference Citation Analysis]
299 Rosati G, Avallone A, Aprile G, Butera A, Reggiardo G, Bilancia D. XELOX and bevacizumab followed by single-agent bevacizumab as maintenance therapy as first-line treatment in elderly patients with advanced colorectal cancer: the boxe study. Cancer Chemother Pharmacol. 2013;71:257-264. [PMID: 23100174 DOI: 10.1007/s00280-012-2004-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
300 Kim S, Dobi E, Jary M, Monnien F, Curtit E, Nguyen T, Lakkis Z, Heyd B, Fratte S, Cléau D. Bifractionated CPT-11 with LV5FU2 infusion (FOLFIRI-3) in combination with bevacizumab: clinical outcomes in first-line metastatic colorectal cancers according to plasma angiopoietin-2 levels. BMC Cancer. 2013;13:611. [PMID: 24373251 DOI: 10.1186/1471-2407-13-611] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
301 Hatake K, Doi T, Uetake H, Takahashi Y, Ishihara Y, Shirao K. Bevacizumab safety in Japanese patients with colorectal cancer. Jpn J Clin Oncol 2016;46:234-40. [DOI: 10.1093/jjco/hyv182] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
302 Santos DA, Alseidi A, Shannon VR, Messick C, Song G, Ledet CR, Lee H, Ngo-huang A, Francis GJ, Asher A. Management of surgical challenges in actively treated cancer patients. Current Problems in Surgery 2017;54:612-54. [DOI: 10.1067/j.cpsurg.2017.11.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
303 Lai Y, Wang C, Civan JM, Palazzo JP, Ye Z, Hyslop T, Lin J, Myers RE, Li B, Jiang B. Effects of Cancer Stage and Treatment Differences on Racial Disparities in Survival From Colon Cancer: A United States Population-Based Study. Gastroenterology. 2016;150:1135-1146. [PMID: 26836586 DOI: 10.1053/j.gastro.2016.01.030] [Cited by in Crossref: 48] [Cited by in F6Publishing: 50] [Article Influence: 8.0] [Reference Citation Analysis]
304 Bennouna J, Sastre J, Arnold D, Österlund P, Greil R, Van Cutsem E, von Moos R, Viéitez JM, Bouché O, Borg C. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 2013;14:29-37. [PMID: 23168366 DOI: 10.1016/s1470-2045(12)70477-1] [Cited by in Crossref: 687] [Cited by in F6Publishing: 357] [Article Influence: 68.7] [Reference Citation Analysis]
305 Vermassen T, Geboes K, De Man M, Laurent S, Decoene E, Lumen N, Delanghe J, Rottey S. Neither creatinine- nor cystatin C-estimated glomerular filtration rate is optimal in oncology patients treated with targeted agents. Nephrol Dial Transplant 2018;33:402-8. [PMID: 28482048 DOI: 10.1093/ndt/gfx063] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
306 Duhoux FP, Machiels JP. Antivascular therapy for epithelial ovarian cancer. J Oncol. 2010;2010:372547. [PMID: 20072701 DOI: 10.1155/2010/372547] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
307 Souza E Silva V, Chinen LT, Abdallah EA, Damascena A, Paludo J, Chojniak R, Dettino AL, de Mello CA, Alves VS, Fanelli MF. Early detection of poor outcome in patients with metastatic colorectal cancer: tumor kinetics evaluated by circulating tumor cells. Onco Targets Ther 2016;9:7503-13. [PMID: 28008271 DOI: 10.2147/OTT.S115268] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.7] [Reference Citation Analysis]
308 Ocvirk J, Moltara ME, Mesti T, Boc M, Rebersek M, Volk N, Benedik J, Hlebanja Z. Bevacizumab plus chemotherapy in elderly patients with previously untreated metastatic colorectal cancer: single center experience. Radiol Oncol 2016;50:226-31. [PMID: 27247556 DOI: 10.1515/raon-2015-0030] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
309 Nordholm-carstensen A, Krarup P, Jorgensen LN, Wille-jørgensen PA, Harling H. Occurrence and survival of synchronous pulmonary metastases in colorectal cancer: A nationwide cohort study. European Journal of Cancer 2014;50:447-56. [DOI: 10.1016/j.ejca.2013.10.009] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
310 Randall LM, Monk BJ. Bevacizumab toxicities and their management in ovarian cancer. Gynecol Oncol 2010;117:497-504. [PMID: 20363017 DOI: 10.1016/j.ygyno.2010.02.021] [Cited by in Crossref: 62] [Cited by in F6Publishing: 64] [Article Influence: 5.2] [Reference Citation Analysis]
311 Geva R, Prenen H, Topal B, Aerts R, Vannoote J, Van Cutsem E. Biologic modulation of chemotherapy in patients with hepatic colorectal metastases: the role of anti-VEGF and anti-EGFR antibodies. J Surg Oncol. 2010;102:937-945. [PMID: 21165996 DOI: 10.1002/jso.21760] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
312 Le Saux O, Falandry C. Toxicity of Cancer Therapies in Older Patients. Curr Oncol Rep 2018;20:64. [PMID: 29896642 DOI: 10.1007/s11912-018-0705-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
313 Vamvakas L, Matikas A, Karampeazis A, Hatzidaki D, Kakolyris S, Christophylakis C, Boukovinas I, Polyzos A, Georgoulias V, Souglakos J. Capecitabine in combination with oxaliplatin and bevacizumab (AXELOX) as 1st line treatment for fit and vulnerable elderly patients (aged & gt; 70 years) with metastatic colorectal cancer (mCRC): a multicenter phase II study of the Hellenic Oncology Research Group (HORG). BMC Cancer. 2014;14:277. [PMID: 24755296 DOI: 10.1186/1471-2407-14-277] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
314 Shuford RA, Cairns AL, Moaven O. Precision Approaches in the Management of Colorectal Cancer: Current Evidence and Latest Advancements Towards Individualizing the Treatment. Cancers (Basel) 2020;12:E3481. [PMID: 33238500 DOI: 10.3390/cancers12113481] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
315 Lu ZH, Peng JH, Wang FL, Yuan YF, Jiang W, Li YH, Wu XJ, Chen G, Ding PR, Li LR, Kong LH, Lin JZ, Zhang RX, Wan DS, Pan ZZ. Bevacizumab with preoperative chemotherapy versus preoperative chemotherapy alone for colorectal cancer liver metastases: a retrospective cohort study. Medicine (Baltimore) 2016;95:e4767. [PMID: 27583930 DOI: 10.1097/MD.0000000000004767] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
316 Iida T, Yabana T, Nakagaki S, Adachi T, Kondo Y. A Rupture of a Lung Metastatic Lesion of Colon Cancer, Leading to Pneumothorax Caused by Bevacizumab. Intern Med. 2016;55:3125-3129. [PMID: 27803405 DOI: 10.2169/internalmedicine.55.7155] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
317 Audisio RA, Papamichael D. Treatment of colorectal cancer in older patients. Nat Rev Gastroenterol Hepatol. 2012;9:716-725. [PMID: 23045000 DOI: 10.1038/nrgastro.2012.196] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
318 Kurniali PC, Hrinczenko B, Al-Janadi A. Management of locally advanced and metastatic colon cancer in elderly patients. World J Gastroenterol 2014; 20(8): 1910-1922 [PMID: 24616568 DOI: 10.3748/wjg.v20.i8.1910] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
319 Van Schaeybroeck S, Lawler M, Johnston B, Salto-tellez M, Lee J, Loughlin P, Wilson R, Johnston PG. Colorectal Cancer. Abeloff's Clinical Oncology. Elsevier; 2014. pp. 1278-1335.e14. [DOI: 10.1016/b978-1-4557-2865-7.00077-1] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
320 García-Foncillas J, Díaz-Rubio E. Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome. Clin Transl Oncol 2010;12:533-42. [PMID: 20709651 DOI: 10.1007/s12094-010-0551-3] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 3.7] [Reference Citation Analysis]
321 Prenen H, Van Cutsem E. Oncological management of unresectable liver metastases. Dig Dis. 2012;30 Suppl 2:137-142. [PMID: 23207946 DOI: 10.1159/000342047] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
322 Meyerhardt JA, Li L, Sanoff HK, Carpenter W, Schrag D. Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer. J Clin Oncol. 2012;30:608-615. [PMID: 22253466 DOI: 10.1200/jco.2011.38.9650] [Cited by in Crossref: 93] [Cited by in F6Publishing: 43] [Article Influence: 9.3] [Reference Citation Analysis]
323 Stein A, Glockzin G, Wienke A, Arnold D, Edelmann T, Hildebrandt B, Hollerbach S, Illerhaus G, Königsrainer A, Richter M, Schlitt HJ, Schmoll HJ. Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature. BMC Cancer 2012;12:356. [PMID: 22897915 DOI: 10.1186/1471-2407-12-356] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
324 Vallerio P, Orenti A, Tosi F, Maistrello M, Palazzini M, Cingarlini S, Colombo P, Bertuzzi M, Spina F, Amatu A, Lombardo R, Prata I, Scaglione F, Vighi GD, Severgnini B, Siena S, Giannattasio C, Boracchi P, Sartore-Bianchi A. Major adverse cardiovascular events associated with VEGF-targeted anticancer tyrosine kinase inhibitors: a real-life study and proposed algorithm for proactive management. ESMO Open 2021;7:100338. [PMID: 34920290 DOI: 10.1016/j.esmoop.2021.100338] [Reference Citation Analysis]
325 Yoshioka Y, Uehara K, Ebata T, Yokoyama Y, Mitsuma A, Ando Y, Nagino M. Postoperative complications following neoadjuvant bevacizumab treatment for advanced colorectal cancer. Surg Today 2014;44:1300-6. [PMID: 23942819 DOI: 10.1007/s00595-013-0686-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
326 Chapin BF, Delacroix SE Jr, Culp SH, Nogueras Gonzalez GM, Tannir NM, Jonasch E, Tamboli P, Wood CG. Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma. Eur Urol 2011;60:964-71. [PMID: 21621907 DOI: 10.1016/j.eururo.2011.05.032] [Cited by in Crossref: 69] [Cited by in F6Publishing: 64] [Article Influence: 6.3] [Reference Citation Analysis]
327 Bruera G, Russo A, Galvano A, Rizzo S, Ricevuto E. Clinical parameters to guide decision-making in elderly metastatic colorectal CANCER patients treated with intensive cytotoxic and anti-angiogenic therapy. Oncotarget 2017;8:37875-83. [PMID: 28053287 DOI: 10.18632/oncotarget.14333] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
328 Figueras J, Lopez-Ben S, Alsina M, Soriano J, Hernandez-Yagüe X, Albiol M, Guardeño R, Codina-Barreras A, Queralt B. Preoperative treatment with bevacizumab in combination with chemotherapy in patients with unresectable metastatic colorectal carcinoma. Clin Transl Oncol 2013;15:460-6. [PMID: 23143951 DOI: 10.1007/s12094-012-0952-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
329 Jeong H, Hong YS, Kim JE, Lim HS, Ahn JB, Shin SJ, Park YS, Kim ST, Han SW, Kim TY, Kim TW. A phase 1 dose-escalation and dose-expansion study to assess the safety and efficacy of CKD-516, a novel vascular disrupting agent, in combination with Irinotecan in patients with previously treated metastatic colorectal cancer. Invest New Drugs 2021;39:1335-47. [PMID: 33829355 DOI: 10.1007/s10637-021-01110-9] [Reference Citation Analysis]
330 Schultheis B, Folprecht G, Kuhlmann J, Ehrenberg R, Hacker UT, Köhne CH, Kornacker M, Boix O, Lettieri J, Krauss J. Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study. Ann Oncol. 2013;24:1560-1567. [PMID: 23493136 DOI: 10.1093/annonc/mdt056] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 6.1] [Reference Citation Analysis]
331 Custodio A, Barriuso J, de Castro J, Martínez-Marín V, Moreno V, Rodríguez-Salas N, Feliu J. Molecular markers to predict outcome to antiangiogenic therapies in colorectal cancer: current evidence and future perspectives. Cancer Treat Rev. 2013;39:908-924. [PMID: 23510598 DOI: 10.1016/j.ctrv.2013.02.004] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 3.0] [Reference Citation Analysis]
332 Gallagher DJ, Kemeny N. Improving Response and Outcomes for Patients With Liver-Limited Metastatic Colorectal Cancer. Clinical Colorectal Cancer 2010;9:S36-43. [DOI: 10.3816/ccc.2010.s.005] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
333 Prenen H, Vecchione L, Van Cutsem E. Role of targeted agents in metastatic colorectal cancer. Targ Oncol 2013;8:83-96. [DOI: 10.1007/s11523-013-0281-x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 4.4] [Reference Citation Analysis]
334 Kabbinavar FF, Flynn PJ, Kozloff M, Ashby MA, Sing A, Barr CE, Grothey A. Gastrointestinal perforation associated with bevacizumab use in metastatic colorectal cancer: results from a large treatment observational cohort study. Eur J Cancer. 2012;48:1126-1132. [PMID: 22424880 DOI: 10.1016/j.ejca.2012.02.052] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 2.6] [Reference Citation Analysis]
335 Allegra CJ, Yothers G, O'Connell MJ, Sharif S, Petrelli NJ, Lopa SH, Wolmark N. Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial. J Clin Oncol. 2013;31:359-364. [PMID: 23233715 DOI: 10.1200/jco.2012.44.4711] [Cited by in Crossref: 145] [Cited by in F6Publishing: 63] [Article Influence: 14.5] [Reference Citation Analysis]
336 Georgiou A, Khakoo S, Edwards P, Minchom A, Kouvelakis K, Kalaitzaki E, Nobar N, Calamai V, Ifijen M, Husson O, Watkins D, Rao S, Chau I, Cunningham D, Starling N. Outcomes of Patients with Early Onset Colorectal Cancer Treated in a UK Specialist Cancer Center. Cancers (Basel) 2019;11:E1558. [PMID: 31615124 DOI: 10.3390/cancers11101558] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
337 De Greef K, Rolfo C, Russo A, Chapelle T, Bronte G, Passiglia F, Coelho A, Papadimitriou K, Peeters M. Multisciplinary management of patients with liver metastasis from colorectal cancer. World J Gastroenterol 2016; 22(32): 7215-7225 [PMID: 27621569 DOI: 10.3748/wjg.v22.i32.7215] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 41] [Article Influence: 6.2] [Reference Citation Analysis]
338 Akgül &, Çetinkaya E, Ersöz Ş, Tez M. Role of surgery in colorectal cancer liver metastases. World J Gastroenterol 2014; 20(20): 6113-6122 [PMID: 24876733 DOI: 10.3748/wjg.v20.i20.6113] [Cited by in CrossRef: 86] [Cited by in F6Publishing: 82] [Article Influence: 10.8] [Reference Citation Analysis]
339 Fourrier-réglat A, Smith D, Rouyer M, Bénichou J, Guimbaud R, Bécouarn Y, Bernard O, Noize P, Moore N, Ravaud A; on behalf of the ETNA study group. Survival outcomes of bevacizumab in first-line metastatic colorectal cancer in a real-life setting: results of the ETNA cohort. Targ Oncol 2014;9:311-9. [DOI: 10.1007/s11523-013-0296-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
340 Li T, Jin X, Dong J, Deng H. Long noncoding RNA ARSR is associated with a poor prognosis in patients with colorectal cancer. J Gene Med 2020;22:e3241. [PMID: 32558022 DOI: 10.1002/jgm.3241] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
341 Bergeat D, Rayar M, Mouchel Y, Merdrignac A, Meunier B, Lièvre A, Boudjema K, Sulpice L. Preoperative bevacizumab and surgery for colorectal liver metastases: a propensity score analysis. Langenbecks Arch Surg 2017;402:57-67. [DOI: 10.1007/s00423-017-1551-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
342 Buchler T, Pavlik T, Melichar B, Bortlicek Z, Usiakova Z, Dusek L, Kiss I, Kohoutek M, Benesova V, Vyzula R, Abrahamova J, Obermannova R. Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis. BMC Cancer 2014;14:323. [PMID: 24884897 DOI: 10.1186/1471-2407-14-323] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
343 Heinemann V, von Weikersthal LF, Decker T, Kiani A, Kaiser F, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Moehler M, Scheithauer W, Held S, Miller-Phillips L, Modest DP, Jung A, Kirchner T, Stintzing S. FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial. Br J Cancer 2021;124:587-94. [PMID: 33154570 DOI: 10.1038/s41416-020-01140-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
344 Sugihara K, Uetake H. Therapeutic strategies for hepatic metastasis of colorectal cancer: overview. J Hepatobiliary Pancreat Sci. 2012;19:523-527. [PMID: 22706522 DOI: 10.1007/s00534-012-0524-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
345 Yildiz R, Benekli M, Ozkan M, Alkis N, Berk V, Kaplan MA, Ciltas A, Karaca H, Durnali AG, Coskun U, Dikilitas M, Sevinc A, Dane F, Yetisyigit T, Dogu GG, Buyukberber S. Bevacizumab every 4 weeks is as effective as every 2 weeks in combination with biweekly FOLFIRI in metastatic colorectal cancer. J Cancer Res Clin Oncol 2012;138:1845-52. [PMID: 22722713 DOI: 10.1007/s00432-012-1264-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
346 Di Fede G, Bronte G, Rizzo S, Rolfo Cervetto C, Cocorullo G, Gulotta G, Bazan V, Russo A. Monoclonal antibodies and antibody fragments: state of the art and future perspectives in the treatment of non-haematological tumors. Expert Opinion on Biological Therapy 2011;11:1433-45. [DOI: 10.1517/14712598.2011.594436] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
347 Tabernero J, Baselga J. Multigene assays to improve assessment of recurrence risk and benefit from chemotherapy in early-stage colon cancer: has the time finally arrived, or are we still stage locked? J Clin Oncol 2010;28:3904-7. [PMID: 20679612 DOI: 10.1200/JCO.2010.30.0806] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
348 Kyriakou F, Kountourakis P, Papamichael D. Targeted agents: review of toxicity in the elderly metastatic colorectal cancer patients. Target Oncol 2011;6:245-51. [PMID: 22068891 DOI: 10.1007/s11523-011-0198-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
349 Dede K, Mersich T, Besznyák I, Zaránd A, Salamon F, Baranyai ZS, Landherr L, Jakab F, Bursics A. Bevacizumab treatment before resection of colorectal liver metastases: safety, recovery of liver function, pathologic assessment. Pathol Oncol Res. 2013;19:501-508. [PMID: 23420304 DOI: 10.1007/s12253-013-9608-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
350 Shankaran V, Mummy D, Koepl L, Blough D, Yim YM, Yu E, Ramsey S. Adverse Events Associated With Bevacizumab and Chemotherapy in Older Patients With Metastatic Colorectal Cancer. Clin Colorectal Cancer. 2012;Dec 28; Epub ahead of print. [PMID: 23276520 DOI: 10.1016/j.clcc.2012.11.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
351 Österlund P, Hermann F. Bevacizumab beyond first disease progression in metastatic colorectal cancer: a review of recent clinical trial data. Colorectal Cancer 2015;4:13-25. [DOI: 10.2217/crc.15.1] [Reference Citation Analysis]
352 Slavicek L, Pavlik T, Tomasek J, Bortlicek Z, Buchler T, Melichar B, Vyzula R, Prausova J, Finek J, Majek O, Dusek L. Efficacy and safety of bevacizumab in elderly patients with metastatic colorectal cancer: results from the Czech population-based registry. BMC Gastroenterol 2014;14:53. [PMID: 24666582 DOI: 10.1186/1471-230X-14-53] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
353 Antonuzzo L, Giommoni E, Pastorelli D, Latiano T, Pavese I, Azzarello D, Aieta M, Pastina I, Di Fabio F, Bertolini A, Corsi DC, Mogavero S, Angelini V, Pazzagli M, Di Costanzo F. Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study. World J Gastroenterol 2015; 21(23): 7281-7288 [PMID: 26109816 DOI: 10.3748/wjg.v21.i23.7281] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
354 Thorat SG, Chikhale RV, Tajne MR. Development and Validation of HPLC and HPTLC Methods for Therapeutic Drug Monitoring of Capecitabine in Colorectal Cancer Patients. J Chromatogr Sci 2020;57:892-900. [PMID: 31609432 DOI: 10.1093/chromsci/bmz067] [Reference Citation Analysis]
355 Bittoni A, Scartozzi M, Giampieri R, Faloppi L, Maccaroni E, Del Prete M, Bianconi M, Cascinu S. The Tower of Babel of liver metastases from colorectal cancer: are we ready for one language? Crit Rev Oncol Hematol 2013;85:332-41. [PMID: 22964298 DOI: 10.1016/j.critrevonc.2012.08.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]